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Summary 
Gliomas are the most common paediatric brain tumours, accounting for about 50% of all 
brain tumours in children. They are typically classified by the putative cell type they arise 
from based on morphology, the location they are found and malignancy grade. The most 
common glioma found in adults is glioblastoma, which is a WHO grade IV tumour with an 
average survival of less than 15 months. Extensive work has gone into characterising, 
modelling and treating this tumour in vivo and in vitro, but it is now clear that glioblastoma 
in children is biologically very different from that in adults. Paediatric high-grade gliomas do, 
however, share their aggressiveness with their adult counterparts, with few patients 
achieving long-term survival - dictating an urgency to find more precise therapies for these 
patients.  
Additionally, relatively little work has focused on low-grade gliomas to date. Nevertheless, 
these tumours also deserve a lot of attention, because low-grade gliomas make up 30-50% 
of all paediatric brain tumours and more than half of all paediatric gliomas. Although the 
tumour itself does not necessarily lead to a massively reduced life span and should rather be 
considered a chronic disease, the impact on the patients’ and families’ lives caused by the 
therapy load and possible recurrences remains a major clinical burden. Unlike high-grade 
gliomas, which are very heterogeneous with multiple oncogenic drivers, most low-grade 
gliomas are driven by alterations in the mitogen-activated protein kinase (MAPK) pathway 
through different mechanisms. Examples are BRAF alterations, FGFR1 mutations, and NTRK 
or MYB fusions.  
After analysing around 200 paediatric glioma samples by whole-genome/whole-exome and 
RNA sequencing within the ICGC PedBrain Tumour Project and the INFORM personalised 
medicine study, fusions involving an additional candidate gene (ALK) were found to be of 
interest in terms of their pattern of occurrence and availability of targeted inhibitors. 
Clinically these fusions arose in an interesting patient population, affecting infants (<2 years 
old) with histologically malignant tumours that however showed outcomes more similar to 
low-grade glioma than glioblastoma. 
PPP1CB:ALK was the most common gene fusion found in this context, which was then 
modelled in vivo using two different state-of-the-art methodologies: in utero electroporation 
and p0 injection using the RCAS-tva system. Through in utero electroporation, a novel mouse 
x 
 
model was generated that nicely recapitulates the human tumours. Different ALK-specific 
inhibitors already used in clinical trials for other tumours, like non-small cell lung cancer or 
neuroblastoma, were tested on the tumour cells in an in vitro sphere culture setting and in 
addition also in vivo on allografted tumour cells. The results show a promising effect of the 
third-line, blood-brain-barrier penetrant ALK inhibitor lorlatinib, with IC50 values below 
1.3nM and a significant increase in lifespan with a decrease in tumour signal, respectively. 
Thus, the project led from the genomic discovery of a novel driving event in paediatric 
glioma through to its modelling and identification of a promising new option for therapy. 
Further proof-of-concept application with other oncogenic combinations leads to the 
conclusion that the mouse model strategy and the methodology behind this can be further 
applied to test other candidate genes and specific inhibitor therapies. The overall aim is thus 
to accelerate the approval of targeted drugs by authorities after running a stratified clinical 
trial on a small infant patient population carrying the gene of interest, to enable patients to 
get the most potent therapy with the fewest side effects. 
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Zusammenfassung 
Gliome sind mit ca. 50% die am häufigsten auftretenden pädiatrischen Hirntumore und 
werden normalerweise nach dem Zelltyp, von dem der Tumor vermutlich entstanden ist, 
klassifiziert. Diese Klassifizierung basiert auf der Morphologie, der Lage und der Malignität 
des Tumors. Bei Erwachsenen ist das Glioblastom das prävalenteste Gliom, welches nach 
WHO Klassifizierung als Grad IV eingestuft ist und die durchschnittliche Überlebenszeit 
beträgt weniger als 15 Monate. Umfangreiche Charakterisierung, Modelletablierung und 
Behandlungen wurden in vitro und in vivo durchgeführt bevor sich nun herausgestellt hat, 
dass sich pädiatrische Glioblastome biologisch stark von denen in Erwachsenen 
unterscheiden. Hochgradige pädiatrische Gliome zeigen die gleiche Aggressivität wie die 
adulte Form, da nur wenige Patienten lange überleben und somit die Dringlichkeit für 
präzisere Therapien für solche Patienten verdeutlicht.  
Aber es wird auch vergleichsweise wenig Arbeit in niedriggradige Gliome investiert. 
Nichtsdestotrotz verdienen diese Tumore ebenso viel Aufmerksamkeit, da mehr als die 
Hälfte aller pädiatrischen Hirntumore (30-50%) niedriggradige Gliome sind. Obwohl der 
Tumor an sich die Lebensdauer nicht zwangsläufig drastisch reduziert und er dadurch eher 
als chronische Krankheit angesehen werden sollte, haben die Therapiefolgen und mögliche 
Rezidive trotzdem sehr drastische Auswirkungen auf die Patienten und deren Familien, und 
bleiben somit eine bedeutende klinische Belastung. Anders als hochgradige Gliome, welche 
aufgrund ihrer vielen onkogenen Auslöser sehr heterogen sind, entstehen die meisten 
niedriggradigen Gliome durch verschiedene Veränderungen im mitogen-activated protein 
kinase (MAPK) Signalweg. Beispiele hierfür sind BRAF Modifikationen, FGFR1 Mutationen, 
und NTRK oder MYB Fusionen. 
Nachdem ca. 200 pädiatrische Gliomproben im Rahmen des ICGC PedBrain Tumour Projekts 
und der INFORM personalisierten Medizinstudie mittels Ganzgenom/Ganzexon- und RNA-
Sequenzierung analysiert wurden, sind wiederholt Fusionen eines zusätzlichen 
Kandidatengens (ALK) aufgetreten, welche aufgrund ihres aufgetretenen Musters und der 
Verfügbarkeit gezielter Inhibitoren interessant wurden. In der Klinik wurden diese Tumore in 
einer interessanten Patientenpopulation (< 2 Jahre) gefunden, da sie histologisch auf einen 
malignen Tumor hinweisen, aber die Überlebensdaten der Patienten eher zu niedriggradigen 
Gliomen als zu Glioblastomen passen.  
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PPP1CB:ALK war die am meisten gefundene Genfusion, die in diesem Zusammenhang 
aufgetreten ist, woraufhin diese in vivo mit zwei verschiedenen Methoden nach dem 
aktuellen Stand der Technik: in utero Elektroporation und p0 Injektion des RCAS-tva Systems, 
nachgestellt wurden. Durch in utero Elektroporation wurde ein neuartiges Mausmodell 
entwickelt, welche die humanen Tumore nachstellt. Verschiedene ALK-spezifische 
Inhibitoren, welche in klinischen Studien schon für andere Tumore wie zum Beispiel dem 
Neuroblastom oder nicht-kleinzelligem Lungenkrebs verwendet werden, wurden an 
Tumorzellesphären in vitro und zusätzlich noch in vivo an allotransplantierten Tumorzellen 
getestet. Die Ergebnisse zeigen eine signifikante Wirkung des third-line, Blut-Hirn-Schranke 
durchlässigen ALK Inhibitors Lorlatinib mit IC50 Werten unter 1.3nM und einem signifikanten 
Anstieg der Lebenserwartung sowie einer Reduktion des Tumorsignals.  
Zusammenfassend deckt dieses Projekt alle Aspekte von genomischer Entdeckung eines 
neuartigen karzinogenen Kandidatengens über dessen Modellentwicklung zur Identifizierung 
und Testung neuer hoffnungsvoller Therapieoptionen ab. Weitere Machbarkeitsstudien mit 
anderen onkogenen Kombinationen ermöglichen es, das Mausmodell und die verwendeten 
Methoden auch für andere Kandidatengene und deren gezielte Inhibitoren einzusetzen. Dies 
hat als endgültiges Ziel, die zielgerichteten Inhibitoren schneller von den Behörden 
genehmigt zu bekommen, nachdem diese in einer stratifizierten klinischen Studie an einer 
kleinen Patientenzahl, die dieses Gen mutiert haben, erfolgreich getestet wurden. So kann 
den Patienten die bestmöglichste Therapie mit den geringsten Nebenwirkungen ermöglicht 
werden. 
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1. Introduction 
1.1 Paediatric Cancer 
Mutations leading to cancer growth can occur anytime in the cellular lineage from the 
development of the fertilised egg to the cells being sequenced in the tumour bulk1. 
These may lead to uncontrolled growth of cells caused by increased cell proliferation 
and decreased apoptosis. In this setting, intrinsic control mechanisms are damaged and 
alterations are made to the normal cell regulatory pathways. Cancer is not only a disease 
that occurs in adults or results from environmental exposures such as UV radiation or 
tobacco smoke. Although cancer is a disease of genetic and epigenetic changes 
accumulating over time, even children (hereafter defined as 0-18 years of age) develop 
neoplasms. Paediatric tumours make up 2% of all cancer cases and are the second most 
common cause of death in this age group, after trauma2. The number of genome-wide 
mutations and copy number changes positively correlate with patient age at diagnosis1,3-
11, with the naturally increased proliferation rate during early development potentially 
meaning that fewer additional alterations are required in order for a cell to become 
cancerous. 
Paediatric central nervous system (CNS) tumours are the second most common (20-25%) 
tumours found in childhood12 (Figure 1). Recently, however, statistics gathered by the 
Central Brain Tumor Registry of the United States (CBTRUS) and others have shown that 
brain and CNS tumours are now the leading cause of cancer-related death in children 
aged 0-19, except in 1-4 year olds, where leukaemia is still the leading cause of 
mortality13. 
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Figure 1. Hierarchial tree of paediatric cancers. Brain and CNS tumours are the second most common 
childhood tumour after leukaemias. These divide into gliomas and other tumours, e.g. Medulloblastoma 
or ATRT. The gliomas can be divided into low- and high-grade gliomas with astrocytomas being the most 
common glioma followed by ependymoma. Pilocytic Astrocytoma (PA) is the most common low-grade 
glioma. 
1.2 Paediatric Neurooncology 
Brain tumours have an overall lower somatic mutational burden than other human 
cancer types (Figure 2) with most paediatric tumours harbouring far fewer mutations 
compared with tumours caused by chronic mutagenic exposures such as lung cancer or 
melanoma (tobacco and UV, respectively)1. Pilocytic astrocytoma is known to be a single 
pathway disease14 with few somatic mutations compared with almost all other cancers. 
 
Figure 2. Somatic mutation prevalence of several different types of cancer in humans. All brain and CNS 
tumours (indicated by the red arrows) are found in the bottom half of the list ranked by somatic mutation 
prevalence. Glioblastoma and Glioma low grade refer to the adult groups. Taken from Alexandrov et al., 
20131. 
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All brain tumour types depicted in Figure 2 are in the bottom half of all tumours listed in 
terms of somatic mutation prevalence, with the paediatric groups (pilocytic astrocytoma 
and medulloblastoma) being in the bottom three. Although the adult groups 
(glioblastoma and glioma low-grade) show a lower mutational burden than other 
cancers depicted, they have a higher mutational burden than the paediatric groups. 
Thus, adult low-grade gliomas have a higher mutational burden than paediatric low-
grade gliomas, which are similar to pilocytic astrocytoma as displayed in Figure 2. 
1.2.1 Gliomas  
Gliomas are the most common CNS tumours in children and young adults15,16 (Figure 3) 
and arise from an uncontrolled growth of cells from the glial lineage16-18. These include 
astrocytomas, oligodendrogliomas, mixed gliomas and ependymomas19,20 (Figure 3) and 
can be classified into different grades depending on the particular type and on the 
presence of aggressive histopathological features in the tumour21. 
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Figure 3. Tumour type incidence in children ages 0-14 and their mortality rates 2007-2011. A. 
Histological CNS tumour diagnoses of children ages 0-14 years of age between 2007 and 2011. B. 
Percentage of total deaths of children ages 0-14 caused by malignant brain and CNS tumours between 
2007 and 2011. Adapted from Ostrom et al. 201513. 
Grade I and II gliomas are commonly considered together and termed as low-grade 
glioma (LGG), with Grades III and IV belonging to the high-grade glioma (HGG) group22,23. 
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LGGs have a much better prognosis than high-grade gliomas. Grading is currently based 
solely on histological features such as the presence of necrosis, pleomorphic nuclei, 
mitosis, giant cells and endothelial proliferation. However, the assessment of these can 
often be highly subjective, leading to different diagnoses between pathologists, often 
with enormous clinical consequences for patient management24. 
1.2.2 High-grade gliomas  
Paediatric HGGs may occur throughout the brain. One noticeable difference from their 
adult counterparts, which are mostly found in the cerebral hemisphere25, is the 
relatively high frequency of tumours in midline structures like the pons (diffuse intrinsic 
pontine glioma, DIPG) or brainstem. The latter locations make resection impossible, 
likely a key reason why these patients therefore have an even worse prognosis than 
patients with hemispheric HGGs (Figure 4). 
 
Figure 4. Location, age at diagnosis and survival of >1000 paediatric HGG and DIPG tumours. A. The left 
side shows an interior view of a sagittal section of the brain, and the right an external view. The different 
colours represent different locations. The size of the circles is proportional to the number of cases, with 
the lighter coloured circles having an unspecific designation. B. Boxplot of age at diagnosis separated by 
location of 1011 cases. ∗∗∗Adjusted p< 0.0001 for all pairwise comparisons, t test. C. Kaplan-Meier survival 
analysis of 811 cases grouped by location. The p-value was calculated by the Log-rank test. Taken from 
Mackay et al., 201726. 
The diffusely infiltrative nature of HGG in general means that even hemispheric tumours 
are not completely resectable, also contributing to the low survival rates27. Luckily, LGGs 
occur more often than HGGs in children and the malignant transformation rate of the 
former is also much lower (7%) than that of adult ‘LGG’ (50%)28,29. High-grade gliomas 
account for around 8-12% of all paediatric CNS tumours30 with a median overall survival 
of 9-15 months31 and a 5-year survival outcome of only 15-35% 32-35 making high-grade 
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gliomas a key priority area for research to try to improve these statistics in the coming 
years. Global annual primary malignant brain and CNS tumour incidences (age-
standardized) currently hold at approximately 37 males and 26 females per 1,000,00036-
38. 
1.2.3 Low-grade gliomas  
Patients with low-grade gliomas on the other hand have a much better survival in 
comparison, but nevertheless suffer from a substantial burden due to (sometimes 
multiple) recurrences and therapy-related side effects. PA, representing ~18% of all 
paediatric brain tumours, is the most common single entity16,39 with paediatric low-
grade gliomas accounting for 30-50% of all CNS tumours in children40-42. Low-grade 
gliomas are mostly found infratentorially (Figure 5), but are very rarely found in the 
brainstem or pons like HGGs (the most common site being the cerebellum). However, 
LGGs found in midline locations often cannot be completely resected, leading to a worse 
prognosis of patients harbouring tumours in those locations since surgical resection is 
the mainstay of therapy for LGGs43. 
 
Figure 5. Location distribution of 623 paediatric low-grade gliomas (PA). PAs most often occur 
infratentorial. Data collected by D. Jones et al., unpublished. High-grade gliomas on the other hand are 
commonly found in the brainstem or pons (Figure 4).  
Adult and paediatric gliomas are histologically and biologically different and should 
therefore not be treated the same way44. However, most clinical trials are focused solely 
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on adult patients, with different dosing and pharmacokinetics of the drugs in addition to 
the different biology meaning that these studies cannot easily be translated to 
children45. 
Luckily, the five and ten year survival of paediatric LGG patients when the tumours are 
completely resected lies at 97% and 95.8%46, respectively, which is contrasting to the 
adult situation47. Adult gliomas have a more aggressive phenotype48 with a higher 
tendency of malignant progression than in children23, leading to a worse survival49-52. 
This is due to fundamental differences in biology, but also in the use of the term ‘low-
grade’. Adult ‘LGGs’ are defined by the presence of IDH mutations (very rare in children), 
and typically show a more diffusely infiltrating growth pattern even at WHO Grade II53-55. 
Thus, low- and high-grade gliomas can be seen as being on two sides of a coin in terms 
of the clinical challenge that they represent. Research on the former concentrates 
mostly on reducing side effects and prolonging the recurrence-free time (increasing 
quality rather than just quantity of survival), whereas for HGGs the main issue is the high 
mortality rates. 
1.2.4 Problems with current therapy regimen and aims of new therapy options 
One fundamental problem with current therapeutic strategies is that they remain largely 
based on a histopathological diagnosis of the tumour. Grading and histopathological 
pattern recognition are challenging, with many of the different described brain tumour 
types showing similar features under the microscope or in magnetic resonance imaging 
(MRI). This obstacle makes it difficult to produce reliable and reproducible diagnoses 
based on histopathology only to act as a foundation for treatment planning56. 
Beyond this, however, standard therapies might not be ideal for every tumour due to a 
variety of reasons as outlined below. Surgical resection is the first option for paediatric 
low-grade gliomas, with gross total resection being a good indicator for overall and 
progression-free survival57-62. In 90% of these cases, no recurrence was observed with a 
10-year overall survival of 90% or more57,59,62-65. However, surgical resection is not 
always possible due to inaccessibility of the tumour, for example if it is located within 
critical surrounding brain areas43. Therefore, other treatment options would be used 
instead, with the most common alternative for LGGs being chemotherapy. However, the 
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slow growth of most LGGs somewhat reduces the efficacy of this treatment, because it 
primarily affects dividing cells. A third option, radiotherapy, is a big burden on the child. 
Radiation-induced side effects can result in long-term morbidity including secondary 
tumours, impaired cognition and vasculopathy66. Thus, chemotherapy and radiotherapy 
can cause long-term side effects in the patients, often impacting their lives as much as 
the tumour growth of LGGs itself, especially when repeatedly administered over the 
lifetime of a patient66. 
These side effects arise due to unspecific treatments, with more than just the tumour 
cells being affected. In addition to tumour recurrences, treatment side effects are one of 
the main factors which may lead to life-long quality of life problems, which is why the 
aim of this and other studies39 is to reduce morbidity and tailor the treatment 
specifically to the molecular features in LGGs, rather than purely increasing the already 
good overall survival rate67. In fact, beyond five years after diagnosis, one-third of 
deaths in LGG patients are from non-tumour related causes (Table 1). Long-term 
therapy-related side effects and tumour-related symptoms occur in most survivors68,69 
and include: seizures (60-85% of LGG70-73), abnormal thyroid function and growth 
hormone deficiency74. Recurrence or progressive disease in PAs occurs in ~80% of 
subtotally resected patients39,47,66 making the therapy-related side effects at least as big 
a burden as the tumour itself - again showing that the research aims of low- and high-
grade gliomas differ and are important to keep in mind. 
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Table 1. Causes of death of paediatric patients with LGG. Taken from Krishnatry et al., 201669. 
 
Less toxic and more specific treatment to attack just the tumour cells are needed to 
reduce these therapy-related side effects75. The key to an improved quality of survival is 
a better understanding of the molecular and genetic disposition, to identify driver 
mutations and tailor a patient’s therapies according to that76. It is hoped that through 
such an approach, the survival rates and survival quality of children with cancer can 
increase again after a slow-down in survival improvement in the last 20 years. The 
currently best way to achieve this is through the field of personalised oncology77, where 
tumours are not just diagnosed by their histological features, but molecular analysis is 
also taken into account in order to improve and standardise both diagnosis and 
treatment. Successes with BRAF and MEK inhibitors, for example, have shown great 
promise with this approach so far78-81. 
1.3 Personalised oncology 
Recent years have shown that histological and radiological diagnosis of brain tumours 
are not sufficient anymore to correctly identify the tumour82-84, because there are too 
many histological similarities85 leading to tremendous inter-observer variation. PA and 
anaplastic astrocytoma with piloid features, for example, show histological overlaps, but 
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are molecularly different, have a very diverse clinical course, and thus require different 
treatments86. In recent years, many groups have worked on further breaking down 
tumour entities and molecularly reclassifying them11,82,83,87-96 to further define tumour 
types, making the entities more specific and objectively-defined, hopefully leaving less 
room for discrepancies.  
The most important impact on molecular classification was the implementation of 
molecular features into the revised World Health Organization (WHO) classification 
published in 201697-100. The aim of including molecular markers for the diagnosis of CNS 
tumours was not only to standardise diagnosis and treatment, but also suggest more 
precisely tailored therapy and be able to more accurately predict the prognosis of the 
disease101. Many papers have evaluated the new classification and how it improved 
diagnosis, and also suggested future directions that should be considered for the next 
classification102-104. 
DNA methylation profiling is an important tool for tumour classification and identifying 
homogeneous molecular subclasses 85,91,105-110, which is regularly used in the clinical 
setting111,112 and in personalised oncology studies like INFORM (http://pediatric-
neurooncology.dkfz.de/index.php/en/diagnostics/inform) and Molecular 
Neuropathology (MNP)2.0 (http://pediatric-neurooncology.dkfz.de/index.php/en/ 
diagnostics/molecular-neuropathology). 
INFORM stands for INdividualized Therapy For Relapsed Malignancies in Childhood, with 
the aim of molecularly characterising relapsed tumours, where no further standard of 
care therapy is available. Recurrent and high risk tumours of different paediatric entities 
are being investigated on a biological level by next generation sequencing to identify the 
individual fingerprint of each tumour113 (Figure 6). This is done on standard of care 
biopsy tissue from patients, with possible molecular drug targets being reported back to 
treating physicians but as yet no formal therapy recommendation given by the INFORM 
team. 
A similar approach for relapsed tumours is taken by the Paediatric Targeted Therapy 
(PTT) 2.0 study (http://pediatric-
neurooncology.dkfz.de/index.php/en/diagnostics/pediatric-targeted-therapy). The aim 
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of this study is to identify druggable molecular targets from the analysis of formalin-
fixed paraffin-embedded (FFPE) tissue. A corresponding blood sample is also profiled, in 
order to reliably distinguish between genetic alterations arising within the tumour tissue 
and germline polymorphisms/mutations. 
 
Figure 6. INFORM registry pipeline. Tumour biopsies and the corresponding blood samples are evaluated 
for quality and then sequenced, before the data is processed by bioinformaticians. From that, targets are 
identified to find matching drugs or suitable trials to treat the patients. Taken from Worst et al.113. 
MNP2.0 on the other hand aims at improving molecular diagnostics in newly-diagnosed 
childhood brain tumours. Every primary brain tumour patient in Germany is eligible to 
be part of this study, and more importantly 80% of them are actually recruited - showing 
how valuable this study is in the molecular era and how much clinicians trust in and rely 
on these results. Analysis is done on FFPE tissue and a corresponding blood sample. 
The principle aim of INFORM and PTT2.0, and a secondary aim of MNP2.0, is to find 
mutational targets that may be druggable with already existing treatments either in 
trials or which have been approved in other tumour entities. With the growing interest 
from oncologists to enrol their patients in these and similar international studies, more 
novel molecular targets can be identified leading to a better understanding of the 
tumour biology and with that greater treatment options. In addition to known targets, 
however, a further aim of the INFORM study (together with initiatives such as the 
International Cancer Genome Consortium (ICGC) PedBrain Tumor Project) is to highlight 
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novel potential targets for intervention. The analyses conducted within these programs 
revealed some novel recurrent genetic fusion or mutation events that became the basis 
of this project. Several of these genetic alterations occur in tumours which cluster 
separately from other genetically distinct groups, and although many were initially 
thought to be HGGs, their survival is more similar to that of LGGs (Figure 7). 
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Figure 7. Identification and survival of new genetically distinct groups. A. Methylation subset of infantile 
‘HGG’ are distinct from other gliomas indicating new molecularly defined entities. B. The prognosis of the 
IHG group (infantile hemispheric glioma, including many ALK-fused tumours) is very similar to that of 
LGGs. Data kindly provided by Matthew Clarke and Chris Jones, ICR, London.  
Table 2 shortly describes some of these newly identified subgroups, with the main focus 
of this thesis being on the role of Anaplastic Lymphoma Kinase (ALK). 
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Table 2. Selected candidate genes as potential oncogenic drivers 
Gene CNS tumour types Approximate 
prevalance 
Schematic diagram of matching 
event modelled here 
ALK Infantile hemispheric 
glioma 
About 20-30% of 
all infant ‘HGG-
like’ tumours in 
patients < 2 years 
old (fusions) 
 
NTRK Pilocytic astrocytoma; 
infantile hemispheric 
glioma; anaplastic 
neuroepithelial tumour 
with condensed nuclei 
(ANTCN) 
2-3% of PA; 20-
30% of infant 
‘HGG’; >50% of 
ANTCN 
(unpublished; 
fusions) 
 
FGFR1 Pilocytic astrocytoma; 
dysembroplastic 
neuroepithelial tumour 
(DNET); 
extraventricular 
neurocytoma (EVN) 
~5% of PA 
(mutation); ~60-
70% of DNET 
(mutation & 
kinase dupl.); 
>60% of EVN 
(mostly 
FGFR1:TACC1) 
 
MYB/ 
MYBL1 
Angiocentric glioma; 
diffuse astrocytoma; 
isomorphic 
astrocytoma 
~100% 
pathognomonic 
of angiocentric 
glioma & 
isomorphic 
astrocytoma; ~10-
20% of paediatric 
diff. astrocytoma 
(fusions) 
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1.4 ALK as an oncogene 
From a total of 90 tyrosine kinase genes identified in the human genome, around 60 
encode for receptor tyrosine kinase proteins114. Receptor tyrosine kinases have been 
shown to not only be involved in normal cellular functions, but when dysregulated, they 
also play a major role in cancer development115. 
One such receptor is ALK, a member of the insulin receptor superfamily116 originally 
identified in 1994 in anaplastic large-cell lymphoma117(ALCL), hence the name, as part of 
the Nucleophosmin (NPM):ALK fusion. This alteration, where the entire NPM gene on 
chromosome 5 is fused to the ALK gene at the 3’ position, was the starting point of many 
more ALK fusions being identified across various other tumour types. 
1.4.1 ALK in NSCLC  
With advances in sequencing technologies, more genetic aberrations involving the 
kinase domain of the ALK gene have since been found118,119. For example the 
Echinoderm microtubule-associated protein-like 4 (EML4):ALK fusion was first identified 
in non-small cell lung cancer (NSCLC) in 2007, independently by two groups120,121. This is 
the most common fusion found in NSCLC, seen in 5% of all NSCLC patients118,120,122-130, 
and is caused by chromosomal rearrangement124. 
In normal tissue, ALK is minimally expressed131 due to controlled pathway activation. As 
a result of a gene fusion event, however, the kinase domain is aberrantly expressed 
leading to an auto- phosphorylation loop and constitutively active fusion protein 
facilitating dimerisation of the receptor subunits and increased downstream pathway 
activation 120,124,125. 
Our group, first within the INFORM project and subsequently in a broader molecular 
analysis of additional brain tumours, found recurrent fusions of ALK with different genes 
at the N –terminus, with PPP1CB being the most common upstream fusion partner of 
ALK (Figure 8).  
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Figure 8. ALK fusion identification and occurrence of PPP1CB:ALK fusion. A. Copy number plot showing 
an increased signal on chromosome 2p at the position of the PPP1CB and ALK genes resulting in a fusion. 
RNA sequencing was used to confirm this. B. Pie chart indicating the frequency of PPP1CB as a fusion 
partner of ALK for 17 patients. Other ALK fusion partners are: CCDC88A (n=2), MSI2, MAD1L1, TPM3, 
KTN1, EML4, PRKAR2A, CLIP2 and SPTBN1, with the latter all seen in only one patient each. 
1.5 ALK inhibition 
1.5.1 ALK inhibitor development 
The ALK receptor is involved in activation of the MAPK pathway, therefore either targets 
downstream of ALK for which inhibitors are already available and more commonly used 
in brain tumours (e.g. MEK) or ALK itself represent druggable targets for inhibition132. An 
inhibitor targeting the tyrosine kinase itself might be better than inhibitors in 
downstream pathways, because ALK signals through additional pathways, which MEK 
inhibitors for example would not target (Figure 9). 
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Within the last seven years, several ALK inhibitors have entered the market and/or are 
being tested in clinical trials, which are separated into three groups: first-, second- or 
third-line inhibitors. 
Crizotinib (PF-2341066) for example was initially developed by Pfizer as a c-Met 
inhibitor, but rapidly progressed in the clinic as one of the first-line ALK inhibitors133,134. 
Only four years after ALK was acknowledged as an important target in cancer with the 
discovery of the EML4:ALK fusion120,121, crizotinib (Xalkori™) was fast-track approved for 
ALK-positive NSCLC by the Food and Drug Administration (FDA). Early successes of 
crizotinib in clinical studies with an objective response rate (ORR) and a median 
progression-free survival (PFS) of 60% and 9.7 months, respectively135 were soon 
shadowed by relapses of patients caused by either ALK fusion gene amplification, 
secondary ALK kinase domain mutations (roughly 1/3 of all acquired resistance) around 
the ATP binding site, activation of other bypass signalling pathways (EGFR, c-KIT), and 
other mechanisms116,123. This led to demand for new generation ALK inhibitors to 
combat the resistance mechanisms of crizotinib. 
Second line inhibitors, ceritinib (LDK-378) and alectinib (CH-5424802), were developed 
in 2014 by Novartis and Chugai/Roche, respectively, and approved by the FDA and 
Japanese Ministry of Health, Labor and Welfare (MHLW) in 2014 (ceritinib) and 2013 
(alectinib). Both are used in patients showing crizotinib resistance136, with ceritinib being 
effective against L1196M, G1269A, I1171T and S1206Y mutations and alectinib against 
L1196M, F1174L, R1275Q and C1156Y116. They were not specifically designed to target 
the resistance mutations, but nevertheless are very effective against wildtype and 
mutant ALK kinases116 more than other serine/threonine or tyrosine kinases. 
Alectinib incorporates a few structural changes to improve its potency, selectivity and 
pharmacokinetic properties over the previous inhibitors. It showed low IC50 values in 
ALK-positive cell lines and high selectivity for ALK compared to other tyrosine 
kinases131,137. According to a clinical study by Watanabe et al., the PFS of EML4-ALK 
fusion-positive patients with NSCLC first treated with crizotinib followed by alectinib 
increased from 6.1 months to 15.2 months138, showing that alectinib overcame the 
crizotinib resistance to provide additional survival benefit. 
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However, there was then another mutation that arose, ALKG1202R, shown to confer 
resistance to all three previously described ALK inhibitors125,139-141. With that, there was 
another need for a further ALK inhibitor that would work in patients showing resistance 
mechanisms, or one that can be given to patients right from the start in the hope that 
this will not induce resistance. The third-line ALK inhibitor lorlatinib (PF-06463922) 
developed by Pfizer, was thus approved by the FDA in April 2017 for ALK-positive 
metastatic NSCLC patients who progressed on another ALK inhibitor142. It is an orally 
available ATP-competitive inhibitor of receptor tyrosine kinases ALK and ROS1143 (Figure 
9). Lorlatinib has cross-reactivity to ROS1 receptor kinase domain due to a phylogenetic 
relation to the ALK receptor kinase domain114, and also exhibits an effect on ROS1 
fusion-positive lung cancers due to this receptor homology144,145. Lorlatinib binds to and 
inhibits ALK and ROS1 kinases and inhibits growth of ALK or ROS1-overexpressing 
tumour cells. However, Zou et al.143 showed that lorlatinib has no substantial activity 
against MET like crizotinib does, further suggesting differences in the mechanism of 
action of the two compounds. 
Lorlatinib was specifically designed to cross the blood-brain barrier (BBB)143,146,147, which 
is a major aspect that needs to be considered when designing compounds for brain 
tumours or brain metastases. The BBB makes it difficult for therapeutic compounds to 
reach their target, therefore it is difficult to achieve effective levels of the drug in the 
tumour148,149. Johnson et al. initially showed BBB penetrance in rats147, with other in 
vivo150 models and in vitro151-157 techniques having been subsequently developed, but 
Collier et al.146 stated that more in vivo models are necessary to confirm this. 
1. Introduction 
19 
 
 
Figure 9. ALK receptor signalling pathway and lorlatinib inhibition. Upon receptor activation by growth 
factors for example, the receptor dimerises and autophosphorylates itself leading to the activation of 
downstream signalling pathways like MEK, JAK/STAT or mTOR. When lorlatinib is administered, it binds to 
the ATP binding pocket on the tyrosine kinase domain of the intracellular portion of the ALK receptor, 
thereby preventing ATP binding and leading to reduced phosphorylation and downstream signalling. 
1.6 Preclinical modelling 
In vivo models are indispensable in research due to the murine genetic and physiological 
similarities to the human158 (90% genome syntheny159,160) and the fact that in vitro 
experiments cannot fully replicate the human disease due to e.g. a lack of 
microenvironmental signalling pathways161,162. Upon isolating cells from an organism, 
not only the gene signatures change154, but other culture-specific issues arise which 
result in an ongoing need for in vivo models. These include the lack of complex 
metabolism that is found in vivo, the unknown factor of the interaction of cells with 
other cell types and their microenvironment, the difficulties of long term exposures of 
drugs in culture medium to recapitulate the situation in humans (including e.g. BBB 
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penetration) and finally the impossibility to convert doses from in vitro system to the 
human163 keeping all the above mentioned variables in mind164. Therefore, to 
accompany in vitro experiments, in vivo analyses are important to get a better idea of 
the physiological processes in cancers within a complex organism. In particular given the 
extensive characterisation of murine systems, it is known that the human and mouse 
CNS are highly preserved across species165,166 and molecular and cellular mechanisms 
are well-conserved159,167-169. 
1.6.1 Advantages and disadvantages of different mouse model approaches 
With recent technical advances, there are now many different ways to generate mouse 
models. The pros and cons will be discussed in this section below. 
One of the most well-known and frequently used mouse model systems for cancer 
research is the xenograft model. Xenografts are tissue or cell grafts (mainly tumour cell 
lines) transplanted from one species to another, mainly from human into 
immunodeficient mice. One benefit of using xenografts is the reduction of clonal 
selection in comparison with cell culture studies. Nonetheless, low passages are desired 
in order to conserve tumour characteristics and keep the tumour closer to the human 
counterpart. Subcutaneous engraftment is the standard used170. With this technique, 
many cell lines from solid tumours and leukaemias have been transplanted into 
xenograft models, threby supplying a variety of tumour models for compound testing171-
174. One step further are orthotopic xenografts, which are implanted into the 
tissue/organ of origin and not just subcutaneously175. That way the microenvironment is 
thought to reflect the original tumour more accurately. To more reliably predict clinical 
activity and clinical behaviour of drugs in human tumour tissues, patient-derived 
xenografts (PDX) have been established. Here, tumour cells from the patients are 
directly injected176 into immune-compromised mice with no or only minimal in vitro 
passaging, which is thought to make them genetically more stable177,178. The mice used 
for xenograft experiments however are adult mice, which get injected with cells from an 
already established tumour. One restriction of this as a model method of choice is 
therefore the differences in the microenvironment in a paediatric setting compared with 
adults. Also, more benign tumours such as LGGs have thus far not been successfully 
grown as xenografts179,180, with a certain degree of aggressiveness of the primary 
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tumour seeming to be required for growth in this setting. Furthermore, some studies 
have found that results from personalised xenograft models have not translated well 
into the clinic181,182, i.e. the expected results that were predicted from the mouse studies 
failed to be recapitulated in patients. The interaction between the tumour cells and the 
surrounding cells in the microenvironment can also not be optimally studied in xenograft 
models due to the lack of the immune system, which may give totally different results in 
response to therapy183. 
In terms of indicating proof-of-concept activity of a compound against one particular 
driving event, xenografts may also harbour too great a genetic heterogeneity with 
multiple cooperating alterations184,185. To avoid this issue, genetically engineered mouse 
models (GEMMs) have been developed that harbour a simplified genetic background 
mimicking what are thought to be the key events in the human tumour. The expression 
of oncogenes in the germline of the mouse has been shown for many years to reliably 
result in cancer formation186. Unlike xenografts, GEMMs can precisely combine 
expression of oncogenes and loss of tumour suppressor genes in either a tissue- or 
whole organism-specific manner187 through recombinant DNA technologies. The 
insertion of genes of interest uses a technology whereby the changes are introduced 
into the mouse genome heritably. Modern GEMMs use inducible systems to have 
temporal and tissue-specific control over the expression of tumour suppressor genes or 
oncogenes170. Although tumour latency is typically low in GEMMs, the generation of 
these germline-altered mice was (prior to the CRISPR era) a long process, which could 
not keep up with the quickly evolving field of tumour sequencing and identification of 
new candidate genes. Whether this may change once more with the expanding use of 
genome-editing techniques, remains to be seen. 
For generation of tumours in a rapid and flexible way which also have more relevance to 
the paediatric setting, different mouse models have previously been described188-191. 
The RCAS/t-va system, for example, has been used for paediatric192 and adult193 glioma 
mouse models and was originally developed by the Holland lab. It allows for somatic 
gene transfer of oncogenic genes into the early postnatal brain (p0-p2) into targeted 
cells expressing the tva receptor. This can further be defined to only be expressed on 
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certain cells, i.e. neuronal cells, where the tva receptor is under a nestin promoter (n-
tva).  
The Replication-Competent ASLV long terminal repeat (LTR) with a Splice acceptor 
(RCAS) vector, which is derived from the SR-A strain of rous sarcoma virus (RSV), a 
member of the avian sarcoma-leukosis virus (ASLV) family, will only replicate in avian 
cells194,195 (for experimental purposes, DF-1 chicken fibroblasts). The gene of interest 
cloned into the RCAS vector will then transfect chicken cells and lead to virus 
production. After three days, the virus-producing cells are injected into the mouse brain 
to infect the target cells – initiating tumour growth if the time point and location of 
injection is suitable for the oncogenic driver. 
If injection post-natally is considered to be too late for the oncogenic gene to exert an 
effect on the right cell population, then the use of another paediatric-relevant 
engineered mouse modelling technique can be of value. In utero electroporation (EP) is 
normally carried out between E10.5 and 14.5 of development. The benefits of using in 
utero electroporation are the region-specificity190 of injection of vectors carrying an 
oncogenic candidate gene and the possibility that multiple genes can be targeted at 
once196 for loss of function and gain of function experiments (Figure 10). The gain of 
function is induced through a transposon vector (PT2K) carrying the gene of interest. 
When injected into the mouse together with a transposase, the gene of interest gets 
excised out of its vector and inserted into an appropriate site in the host DNA sequence 
depending on the transposon system used. The CRISPR (Clustered Regularly Interspaced 
Short Palindromic Repeats)/Cas9 system is responsible for inducing loss of function in 
desired genes, mainly tumour suppressor genes like p53 or cdkn2a. In this case a single 
guide RNA (gRNA) composed of 20 nucleotides directs the Cas9 nuclease enzyme to a 
specific target site at the locus that needs to be cut. This double strand break results in 
either of two repair mechanisms - Non-Homologous End Joining (NHEJ) or Homology-
Directed Repair (HDR)197. These are error-prone, typically resulting in Indels (Insertions 
and deletions) that introduce a frameshift and thereby non-functional proteins. 
1. Introduction 
23 
 
 
Figure 10. Mechanisms of gain- and loss of function in in utero electroporation mouse models. A. When 
the transposase enzyme and the transposon vector containing a gene of interest come together, the 
former excises the gene of interest from the vector and inserts it into a suitable DNA sequence leading to 
gain of function. B. Loss of function is achieved with the CRISPR/Cas9 technology, where a 20 nucleotide 
single guide RNA guides the Cas9 enzyme to the genomic target sequence leading to a double strand 
break. This activates either NHEJ or HDR repair mechanisms resulting in Indels and subsequently 
dysfunctional proteins. Taken from Lampreht Tratar et al.175.  
Taking into account the above listed advantages and disadvantages of the described 
model systems, the RCAS/tv-a and in utero EP systems were chosen for this study to try 
and establish mouse models for the different candidate genes identified. Drug response 
tests were conducted both in vitro and in vivo, to firstly see if and how they differ, and 
secondly to have two independent pieces of evidence for justifying the possible 
effectiveness of a given drug. Nevertheless, one needs to keep in mind that the mouse is 
only a model organism and all results should be carefully considered for their predictive 
value and re-tested in the human situation. 
1.7 Future applications and hopes 
More, and more precise, clinical trials are urgently needed for children with paediatric 
gliomas, because the current standard of therapy is either a) largely ineffective (for 
HGG) or b) associated with significant toxicity (for LGG), and medications are frequently 
prescribed to children on a trial-and-error basis without specific knowledge about the 
dosing, efficacy and safety of the drug in children198-200. With specific mouse model 
development and subsequent preclinical testing, the bench-to-bedside process will 
hopefully decrease in time enabling the patients to get more specific therapy faster 
based on their genetic alterations. Kolb et al.201 showed that improved MEK inhibitors 
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have led to not only successful preclinical testing in mouse models, but also initiation of 
a clinical trial in LGG patients with such an inhibitor, selumetinib (AZD6244; 
NCT01089101) - discovered by Array BioPharma and licensed to AstraZeneca. 
It is hoped that this study may represent an important part of the preclinical pipeline 
towards lorlatinib approval in children with ALK-altered tumours in particular (hopefully 
with the initiation of a clinical trial in infant patients harbouring an ALK alteration), and 
in general a useful proof-of-concept methodology for accelerating regulatory approval of 
targeted treatments for childhood cancer. 
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2. Materials & Methods 
2.1 Materials 
2.1.1 Solutions, Buffer, Media, Reagents 
Solution/Buffer/Media/Reagents Supplier 
Accumax eBioscience, Karlsruhe, Germany 
Albumin fraction V Carl Roth, Karlsruhe, Germany 
ATP solution (25-mM) Epicentre, Madison, USA 
B-27 supplement (50x) Thermo Fisher Scientific, Karlsruhe, 
Germany 
Biotin-blocking system Agilent, Santa Clara, USA 
Boric acid Fisher Bioreagents, Pittsburgh, USA 
cOmplete™ Mini EDTA-free protease 
inhibitor cocktail tablets 
Roche Diagnostics, Mannheim, Germany 
CutSmart® buffer (10x) New England Biolabs, Ipswich, USA 
Dako antibody diluent Agilent, Santa Clara, USA 
DAPI fluoromount-G® mounting medium Thermo Fisher Scientific, Karlsruhe, 
Germany 
DMEM/F-12 medium Thermo Fisher Scientific, Karlsruhe, 
Germany 
ECL western blotting reagents Merck, Darmstadt, Germany 
EGF-basic, recombinant human protein PeproTech, Hamburg, Germany 
Eosin G solution 0.5% in water Carl Roth, Karlsruhe, Germany 
Ethanol absolute Fisher Chemical, Pittsburgh, USA 
Eukitt® mounting medium O. Kindler GmbH, Freiburg, Germany 
Fast digest buffer (10x) Thermo Fisher Scientific, Karlsruhe, 
Germany 
Fast green FCF Merck, Darmstadt, Germany 
FGF-basic, recombinant human protein PeproTech, Hamburg, Germany 
Formalin solution, neutral buffered, 10% Merck, Darmstadt, Germany 
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FuGene HD transfection reagent Promega, Madison, USA 
Glycine Merck, Darmstadt, Germany 
Heparin sodium Merck, Darmstadt, Germany 
HotStarTaq plus master mix Qiagen, Hilden, Germany 
Hydrochloric acid puriss. p.a. reag. ph. eur. 
≥37%  
Merck, Darmstadt, Germany 
Hydrochloric acid, 1mol/l (1N) VWR International, Bruchsal, Germany 
Laminin Merck, Darmstadt, Germany 
Luciferin BioVision, San Francisco, USA 
Mayer’s haematoxylin solution AppliChem, Darmstadt, Germany 
Methanol Fisher Chemical, Pittsburgh, USA 
Neurobasal-A medium Thermo Fisher Scientific, Karlsruhe, 
Germany 
Normal donkey serum Merck Millipore, Darmstadt, Germany 
NP-40 lysis buffer Thermo Fisher Scientific, Karlsruhe, 
Germany 
NuPAGE™ 4-12% Bis-Tris gel Thermo Fisher Scientific, Karlsruhe, 
Germany 
NuPAGE™ antioxidant Thermo Fisher Scientific, Karlsruhe, 
Germany 
NuPAGE™ LDS sample buffer (4x) Thermo Fisher Scientific, Karlsruhe, 
Germany 
NuPAGE™ MES SDS running buffer (20x) Thermo Fisher Scientific, Karlsruhe, 
Germany 
Opti-MEM Thermo Fisher Scientific, Karlsruhe, 
Germany 
Paraformaldehyde solution 4% in PBS Santa Cruz Biotechnology, Dallas, USA 
PDGF-AA recombinant human protein PeproTech, Hamburg, Germany 
Plasmid-safe™ ATP-dependent DNase Epicentre, Madison, USA 
Plasmid-Safe™ reaction buffer (10x) Epicentre, Madison, USA 
Poly(ethylene glycol), average Mn300 Merck, Darmstadt, Germany 
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Poly-L-Ornithine hydrobromide Merck, Darmstadt, Germany 
Protease/Phosphatase inhibitor cocktail 
(100x) 
Cell Signaling Technology, Danvers, USA 
Proteinase K Promega, Madison, USA 
RIPA lysis buffer (10x) Merck, Darmstadt, Germany 
SOC medium Made myself 
Sodium chloride Merck, Darmstadt, Germany 
ß-Mercaptoethanol Merck, Darmstadt, Germany 
Synth-a-freeze cryopreservation medium Thermo Fisher Scientific, Karlsruhe, 
Germany 
T4 DNA ligase reaction buffer New England Biolabs, Ipswich, USA 
TC10 trypan blue dye BioRad, Hercules, USA 
TRANSIT®-LT1 transfection reagent Mirus Bio, Madison, USA 
Trisma base AppliChem, Darmstadt, Germany 
Tri-sodium citrate dehydrate Merck, Darmstadt, Germany 
Triton™ X-100 Merck, Darmstadt, Germany 
Trypsin-EDTA (10x) Merck, Darmstadt, Germany 
Tween®20 Merck, Darmstadt, Germany 
UltraPure™DNase/RNase-free distilled water Thermo Fisher Scientific, Karlsruhe, 
Germany 
Water, double-processed, cell culture tested Merck, Darmstadt, Germany 
Xylene VWR International, Bruchsal, Germany 
 
2.1.2 Antibodies 
Antigen Clone Primary (P)/ 
Secondary (S) 
Dilution  Supplier Catalogue 
number 
Alexa Fluor® 568 
donkey anti-rabbit 
IgG   
N/A S 1:400 Thermo 
Fisher 
Scientific, 
Karlsruhe, 
Germany 
A10042 
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ALK (Y1278 + 
Y1282 + Y1283) 
rabbit 
N/A P 1:200 Bioss, 
Woburn, 
USA 
bs-3021R 
ALK/CD246 rabbit  N/A P 1:300 Thermo 
Fisher 
Scientific, 
Karlsruhe, 
Germany 
51-3900 
Cleaved Caspase-3 
(Asp175) rabbit 
5A1E P 1:500 Cell 
Signaling 
Technology, 
Danvers, 
USA 
9664 
GAPDH mouse 6C5 P 1:5000 Millipore, 
Darmstadt, 
Germany 
CB1001 
HA-tag rabbit C29F4 P 1:800 (IHC, 
IF)/ 1:3000 
(WB) 
Cell 
Signaling 
Technology, 
Danvers, 
USA 
3724 
IgG-HRP goat anti-
mouse 
N/A S 1:3000 Cell 
Signaling 
Technology, 
Danvers, 
USA 
7076 
IgG-HRP goat anti-
rabbit 
N/A S 1:2000 Cell 
Signaling 
Technology, 
Danvers, 
USA 
7074 
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Ki-67 rabbit B56 P 1:1000 BD 
Biosciences, 
San Jose, 
USA 
550609 
Phospho-ALK 
(Tyr1604) rabbit  
Tyr1604 P 1:1000 Cell 
Signaling 
Technology, 
Danvers, 
USA 
3341 
 
2.1.3 Kits 
Name Supplier 
CellTiter-Glo luminescent cell viability assay Promega, Madison, USA 
CloneJET PCR cloning kit Thermo Fisher Scientific, Karlsruhe, 
Germany 
Dead cell apoptosis kit with annexin V FITC 
and PI, for flow cytometry 
Life Technologies, Karlsruhe, Germany 
DNeasy blood & tissue kit Qiagen, Hilden, Germany 
Endofree plasmid maxi kit Qiagen, Hilden, Germany 
LSAB+ dako real detection systems Agilent, Santa Clara, USA 
PRECISOR high-fidelity DNA polymerase Biocat, Heidelberg, Germany 
Propidium iodide flow cytometry kit Abcam, Cambridge, United Kingdom 
QIAprep spin miniprep kit Qiagen, Hilden, Germany 
QIAquick gel extraction kit Qiagen, Hilden, Germany 
QIAquick PCR purification kit Qiagen, Hilden, Germany 
Quick ligation™ kit New England Biolabs, Ipswich, USA 
SuperScript™ II reverse transcriptase Thermo Fisher Scientific, Karlsruhe, 
Germany 
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2.1.4 Mouse Line 
Strain Supplier Genotype 
CD1 Central Animal Facility of 
the DKFZ Heidelberg / 
Envigo 
Wild-type 
NSG Central Animal Facility of 
the DKFZ Heidelberg 
PrkdcscidIL2rgnull 
N-tva Central Animal Facility of 
the DKFZ Heidelberg/ 
Jackson Laboratory 
Wild-type; Nestin 
promoter-driven tva 
receptor 
XFM Central Animal Facility of 
the DKFZ Heidelberg/ 
Jackson Laboratory 
Cdkn2a-KO; Ptenfl/fl¸ Nestin 
promoter-driven tva 
receptor 
 
 
2.1.5 Pharmaceutical drugs and inhibitors 
Drug Effect Supplier 
Alectinib ALK inhibitor Selleck Chemicals, Munich, 
Germany 
AZD4547 FGFR inhibitor Selleck Chemicals, Munich, 
Germany 
Ceritinib ALK inhibitor Selleck Chemicals, Munich, 
Germany 
Crizotinib ALK/c-MET inhibitor Selleck Chemicals, Munich, 
Germany 
Dovitinib Multitargeted RTK inhibitor Selleck Chemicals, Munich, 
Germany 
Entrectinib pan-TrkA/B/C, ROS1 and 
ALK inhibitor 
Selleck Chemicals, Munich, 
Germany 
Infigratinib FGFR inhibitor Selleck Chemicals, Munich, 
Germany 
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Larotrectinib TRK inhibitor Selleck Chemicals, Munich, 
Germany 
Lorlatinib ALK/Ros1 inhibitor Selleck Chemicals, Munich, 
Germany 
Merestinib MET tyrosine kinase 
inhibitor 
Selleck Chemicals, Munich, 
Germany 
Metamizol Analgetica WDT, Garbsen, Germany 
PD173074 FGFR1 inhibitor Selleck Chemicals, Munich, 
Germany 
Ponatinib Abl, PDGFRα, VEGFR2, 
FGFR1 and Src inhibitor 
Selleck Chemicals, Munich, 
Germany 
Rimadyl® (Carprofen) NSAID Zoetis, Berlin, Germany 
Temozolomide (TMZ) SN-1 alkylating agent Selleck Chemicals, Munich, 
Germany 
 
2.1.6 Cells 
Name Cell type Supplier Biological Source 
BI#169 PPP1CB:ALK-
positive 
Generated through 
in utero EP 
Mouse brain 
BI#190 PPP1CB:ALK-
positive 
Generated through 
in utero EP 
Mouse brain 
BI#191 PPP1CB:ALK-
positive 
Generated through 
in utero EP 
Mouse brain 
BI#238 QKI:NTRK2-positive Generated through 
in utero EP 
Mouse brain 
BI#239 QKI:NTRK2-positive Generated through 
in utero EP 
Mouse brain 
BI#271 PPP1CB:ALK-
positive 
Generated through 
in utero EP 
Mouse brain 
BI#283 PPP1CB:ALK-
positive 
Generated through 
in utero EP 
Mouse brain 
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BI#298 QKI:NTRK2-positive Generated through 
in utero EP 
Mouse brain 
BI#299 QKI:NTRK2-positive Generated through 
in utero EP 
Mouse brain 
BI#300 QKI:NTRK2-positive Generated through 
in utero EP 
Mouse brain 
BI#301 QKI:NTRK2-positive Generated through 
in utero EP 
Mouse brain 
BI#386 PPP1CB:ALK-
positive 
Generated through 
in utero EP 
Mouse brain 
HEK-293 Human Embryonic 
kidney 
ATCC, Wesel, 
Germany 
Human Embryonic 
kidney 
UMNSAH/DF-1 Chicken fibroblasts 
spontaneously 
transformed 
ATCC, Wesel, 
Germany 
Gallus gallus 
embryo 
 
2.1.7 Oligonucleotides 
Primer Sequence 5‘ to 3‘ 
4/5_PJET_rev (pJET) GCATCTCGAGGAGACGTCAAGCGTAATCTGGAACATCGTATG
GGTAGCGGCGTTTGAGTCCGC 
BI_alkfusion_EP_for ACGTGAATTCACCATGGCGGACGGGGAGCT 
BI_alkfusion_EP_rev ACGTCTCGAGTCAAGCGTAATCTGGAACATCGTATGGGTAGG
GCCCAGGCTGGTTCAT 
BI_alkfusion_HAtag_for ACGTGCGGCCGCACCATGGCGGACGGGGAGCT 
BI_alkfusion_HAtag_rev ACGTATCGATTCAAGCGTAATCTGGAACATCGTATGGGTAGG
GCCCAGGCTGGTTCAT 
BI_alkfusion_inthemiddle CGACTACAACCCCAACTACTG 
BI_alkfusion_theend GGTACCTCTGTTCAGGCTAC 
BI_alkfusion_thestart CAGCGGTGCTTCCAATTCC 
Crispr_seq_2 ACTATCATATGCTTACCGTAAC 
CRISPRseq3 CATATGCTTACCGTAACTTGAAAG 
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FGFR1_mut_EP_for ACGTCGTCTCGAATTCACCATGTGGAGCTGGAAGTGCC 
FGFR1_mut_inthemiddle1 CTTCACTTAAGAAATGTCTCCTTTG 
FGFR1_mut_inthemiddle2 GGAGGCCCCCAGGGCT 
FGFR1_mut_startofmiddle ATGTGTAAGGTGTACAGTGACC 
FGFR1_mut_thestart CCGCAGCCGACAGCGAA 
FGFR1-mutation_for (pJET) ACGTCGTCTCGCTAGCACCATGTGGAGCTGGAAGTGCC 
FRFR1_mut_theend TGTCCATGCCCCTGGACC 
MYB:QKI_end ATGAGTACCCCTACACATTGG 
MYB:QKI_fusion_for CTCACGTCTCATTCTGCAGAAGGAGAAGACAGCCT 
MYB:QKI_fusion_rev CTCACGTCTCAAGAATCTATAAATTGGAGTGTTTCTG 
New_1_EP_rev (pJET) GCATCTCGAGGAGACGCTAAGCGTAATCTGGAACATCGTATG
GGTAGCCTAGAATGTCCAGGTAGAC 
New_4/5_EP_rev CATGCTCGAGTCAAGCGTAATCTGGAACATCGTATGGGTAGC
GGCGTTTGAGTCCGC 
NEW_MYB:QKI_rev (pJET) ACGTCTCGAGCTAAGCGTAATCTGGAACATCGTATGGGTAGT
TGCCGGTGGCGGCTC 
pCAGGS_seq_for TCCATCTCCAGCCTCGGGGC 
PT2K_forward_seq GCTCTAGCTAGAGCCTCTGCTAACC 
PT2K_MYB:PCDHGA1/QKI_ 
for 
ACGTCGTCTCGAATTCACCATGGCCCGAAGACCCCGG 
PT2K_MYB:QKI_rev ACGTCTCGAGTTAAGCGTAATCTGGAACATCGTATGGGTAGT
TGCCGGTGGCGGCTCG 
PT2K_reverse_seq TAAACCAAATACTCATTCTG 
px330_insert_rev_further GTCAATAGGGGGCGTACTT 
px330_seq_for CCTTTTGCTGGCCTTTTGCTC 
pX330_seq_rev_new CAGCCAGGCGGGCCATTTA 
QKI:NTRK2_EP_for ACGTGAATTC ACCATGGTCGGGGAAATGGAAACG 
QKI:NTRK2_for ACGTCGTCTCGCTAGCACCATGGTCGGGGAAATGGAAACG 
QKI:NTRK2_theend GGCCGAGTCCTGCAGCG 
QKI:NTRK2_thestart GTGTCATTGTACATGTCTTTCCG 
RCAS_FGFR1dupl/mut_for ACGTGCGGCCGCACCATGTGGAGCTGGAAGTGCCTC 
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RCAS_FGFR1dupl/mut_rev ACGTATCGATTCAAGCGTAATCTGGAACATCGTATGGGTAGC
GGCGTTTGAGTCCGCC 
RCAS_MYB:PCDHGA1/QKI_
for 
ACGTGCGGCCGCACCATGGCCCGAAGACCCCGGCA 
RCAS_MYB:QKI_rev ACGTATCGATTTAAGCGTAATCTGGAACATCGTATGGGTAGT
TGCCGGTGGCGGCTCG 
RCAS_NACC2:NTRK2/QKI: 
NTRK2_rev_new 
TCGAATCGATCTAAGCGTAATCTGGAACATCGTATGGGTAGC
CTAGAATGTCCAGGTAGAC 
RCAS_QKI:NTRK2_for_new ACGTGCGGCCGCACCATGGTCGGGGAAATGGAAACG 
 
 
2.1.8 Plastics 
Designation Supplier 
8-well nunc™ lab-tek™ II chamber slides™ Thermo Fisher Scientific, Karlsruhe, 
Germany 
Cell strainer 40µm NeoLab Migge, Heidelberg, Germany 
Centrifuge tube, 15ml TPP, Klettgau, Germany 
Centrifuge tube, 50ml TPP, Klettgau, Germany 
Corning® Costar® Stripette® serological pipette, 
10ml 
Merck, Darmstadt, Germany 
Corning® Costar® Stripette® serological pipette, 
25ml 
Merck, Darmstadt, Germany 
Corning® costar® stripette® serological pipette, 
50ml 
Merck, Darmstadt, Germany 
Corning® costar® stripette® serological pipette, 
5ml 
Merck, Darmstadt, Germany 
Electroporation cuvettes 1mm Biozym, Hessisch Oldendorf, Germany 
Eppendorf tube® 1,5ml Eppendorf, Hamburg, Germany 
Eppendorf tube® 2,0ml Eppendorf, Hamburg, Germany 
Millex®-GS filter unit, 0.22 µm Merck Millipore, Darmstadt, Germany 
Millex®-GS filter unit, 0.45 µm Merck Millipore, Darmstadt, Germany 
2. Materials & Methods 
35 
 
Millipore express® PLUS membrane 500ml 
funnel, 0.22µm GP 
Merck Millipore, Darmstadt, Germany 
PCR tubes Biozym, Hessisch Oldendorf, Germany 
Petri dishes, Ø 100mm VWR International, Bruchsal, 
Germany 
SafeSeal-tips® professional, 10µl Biozym, Hessisch Oldendorf, Germany 
SafeSeal-tips® professional, 1000µl Biozym, Hessisch Oldendorf, Germany 
SafeSeal-tips® professional, 20µl Biozym, Hessisch Oldendorf, Germany 
SafeSeal-tips® professional, 200µl Biozym, Hessisch Oldendorf, Germany 
Stericup® receiver Bottle, 500ml  Merck Millipore, Darmstadt, Germany 
SurPhob® Tips, 10µl Biozym, Hessisch Oldendorf, Germany 
SurPhob® Tips, 1000µl Biozym, Hessisch Oldendorf, Germany 
SurPhob® Tips, 200µl Biozym, Hessisch Oldendorf, Germany 
SW41 ultracentrifuge tubes Beckman Coulter, Krefeld, Germany 
Tissue culture dish, Ø 100mm TPP, Klettgau, Germany 
Tissue culture flask 25cm2 TPP, Klettgau, Germany 
Tissue culture flask 75cm2 TPP, Klettgau, Germany 
Tissue culture flask 150cm2 TPP, Klettgau, Germany 
 
2.1.9 Electrical equipment 
Description Specification Company 
Automated cell counter TC20™ BioRad, Hercules, USA 
Cell analyser FACSCanto™ II BD Biosciences, San Jose, 
USA 
Centrifuge Varifuge 3.0R Heraeus, Hanau, Germany 
Centrifuge Multifuge 3s Heraeus, Hanau, Germany 
Chemiluminescence imager ECL Chemostar Intas, Göttingen, Germany 
CO2 incubator Heracell™ 150i Thermo Fisher Scientific, 
Karlsruhe, Germany 
CO2 incubator Innova® CO-48 New Brunswick Scientific, 
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Edison, USA 
Cold plate for cooling paraffin 
blocks 
EG1130 Leica, Wetzlar, Germany 
Electrophoresis power supply Consort EV231 Merck, Darmstadt, Germany 
Electroporation apparatus MicroPulser™ BioRad, Hercules, USA 
Embedding workstation HistoStar™ Thermo Fisher Scientific, 
Karlsruhe, Germany 
Epi-fluorescence illuminator Intensilight C-HGFI Nikon Instruments, 
Amsterdam, The 
Netherlands 
Fast Real-Time PCR system 7900HT Thermo Fisher Scientific, 
Karlsruhe, Germany 
Flaming/Brown micropipette 
puller 
P-97 Sutter Instrument, Novato, 
Germany 
Fluorescent microscope Axio Imager.M2 Zeiss, Oberkochen, Germany 
Gel electrophoresis Mini-PROTEAN® Tetra 
System 
BioRad, Hercules, USA 
Horizontal mixer RM5-30 V CAT M. Zipperer GmbH, 
Ballrechten-Dottingen, 
Germany 
In vivo pre-clinical imaging 
system 
IVIS® Lumina LT Series III PerkinElmer, Waltham, USA 
Incubation hood Certomat® HK Sartorius Group, Göttingen, 
Germany 
Inverted microscope Eclipse TS100 Nikon Instruments, 
Amsterdam, The 
Netherlands 
Mastercycler Epgradient S Eppendorf, Hamburg, 
Germany 
Microcentrifuge Fresco™ 17 Thermo Fisher Scientific, 
Karlsruhe, Germany 
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Microgrinder EG-45 Narishige, Tokyo, Japan 
Microplate reader Mithras LB 940 Berthold Technologies, Bad 
Wildbach, Germany 
Mini centrifuge Spectrafuge NeoLab Migge, Heidelberg, 
Germany 
Mini-Cell electrophoresis 
system 
XCell SureLock™ Thermo Fisher Scientific, 
Karlsruhe, Germany 
Orbital shaker Seastar™ Thermo Fisher Scientific, 
Karlsruhe, Germany 
Precision scales 1200-3A Kern PLJ, Balingen, Germany 
Rotary disc microtome DSC1 Leica, Wetzlar, Germany 
Slide scanner PrimeHisto XE NeoLab Migge, Heidelberg, 
Germany 
Spectrophotometer NanoDrop® ND-1000 Thermo Fisher Scientific, 
Karlsruhe, Germany 
Spin tissue processor Microm STP 120 Thermo Fisher Scientific, 
Karlsruhe, Germany 
Thermal cycler GeneAmp® PCR System 
9700 
Thermo Fisher Scientific, 
Karlsruhe, Germany 
Thermal cycler DNA Engine Dyad® BioRad, Hercules, USA 
Thermo shaker PHMT-PSC24 Grant Instruments™, 
Shepreth, United Kingdom 
Ultrasonic bath  Arrayit®, Sunnyvale, USA 
Ultraviolet transilluminator 
system 
Gel Doc 2000  BioRad, Hercules, USA 
Water bath 1002 GFL, Burgwedel, Germany 
Water bath HI1210 Leica, Wetzlar, Germany 
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2.1.10 Enzymes 
Enzyme Supplier 
ClaI New England Biolabs, Ipswich, USA 
FastDigest EcoRI Thermo Fisher Scientific, Karlsruhe, 
Germany 
FastDigest Esp3I Thermo Fisher Scientific, Karlsruhe, 
Germany 
FastDigest PstI Thermo Fisher Scientific, Karlsruhe, 
Germany 
FastDigest SalI Thermo Fisher Scientific, Karlsruhe, 
Germany 
FastDigest XhoI Thermo Fisher Scientific, Karlsruhe, 
Germany 
KpnI-HF® New England Biolabs, Ipswich, USA 
NheI Thermo Fisher Scientific, Karlsruhe, 
Germany 
NotI-HF® New England Biolabs, Ipswich, USA 
PciI New England Biolabs, Ipswich, USA 
Xba1 Thermo Fisher Scientific, Karlsruhe, 
Germany 
 
2.1.11 Plasmids 
Plasmid Source 
Lentiguide-puro Marc Zuckermann, DKFZ, Heidelberg, 
Germany 
pCAGGS Sato Y. et al.202 
pCW-Cas9 Marc Zuckermann, DKFZ, Heidelberg, 
Germany 
pJET1.2 blunt vector Thermo Fisher Scientific, Karlsruhe, 
Germany 
pMD2.G  Kathrin Schramm, DKFZ, Heidelberg, 
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Germany 
psPAX2  Kathrin Schramm, DKFZ, Heidelberg, 
Germany 
PT2K IRES-Luciferase Sato Y. et al.203 
pX330 Feng Zhang, MIT, Cambridge, USA 
RCAS Kathrin Schramm, DKFZ, Heidelberg, 
Germany 
Transposase Marc Zuckermann, DKFZ, Heidelberg, 
Germany 
 
2.1.12 Software 
Software Source 
EndNote X7 Thomson Reuters, Carlsbad, USA 
FACS Diva BD Biosciences, San Jose, USA 
FlowJo™ v10 BD Biosciences, San Jose, USA 
Living Image® PerkinElmer, Waltham, USA 
Microsoft Excel 2010 Microsoft, Redmond, USA 
Microsoft PowerPoint 2010 Microsoft, Redmond, USA 
Microsoft Word 2010 Microsoft, Redmond, USA 
Multiple Sequence Alignment (MUSCLE) EMBL-EBI, Hinxton, United Kingdom 
NCBI Align Sequences Nucleotide BLAST NCBI, Bethesda, USA 
NEBioCalculator New England Biolabs, Ipswich, USA 
Prism 5.04 GraphPad GraphPad Software Inc., La Jolla, USA 
Sequence Scanner v1.0 Thermo Fisher Scientific, Karlsruhe, 
Germany 
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2.1.13 Miscellaneous 
Material Company 
1 kb DNA ladder Thermo Fisher Scientific, Karlsruhe, 
Germany 
100 bp DNA ladder Thermo Fisher Scientific, Karlsruhe, 
Germany 
Borosilicate glass capillaries World Precision Instruments, Sarasota, 
USA 
Cover slips, menzel-gläser VWR International, Bruchsal, Germany 
Dako pen Agilent, Santa Clara, USA 
Disposable scalpel No.10 pfm medical, Cologne, Germany 
E.cloni 10G ELITE electrocompetent cells Biocat, Heidelberg, Germany 
Histoacryl® tissue glue B.Braun Surgical, Melsungen, Germany 
Isoflo® Zoetis, Berlin, Germany 
NEB 10-ß competent E.coli New England Biolabs, Ipswich, USA 
One shot Stbl3 chemically competent E.coli Thermo Fisher Scientific, Karlsruhe, 
Germany 
One shot TOP10 chemically competent 
E.coli 
Thermo Fisher Scientific, Karlsruhe, 
Germany 
Platinium tweezer electrode, 3mm 
diameter 
BTX, Holliston, USA 
PVDF transfer membrane Thermo Fisher Scientific, Karlsruhe, 
Germany 
Spectra™ multicolor broad range protein 
ladder 
Thermo Fisher Scientific, Karlsruhe, 
Germany 
Superfrost plus microscope slides, menzel-
gläser 
VWR International, Bruchsal, Germany 
Whatman® cellulose chromatography 
paper 
Merck, Darmstadt, Germany 
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2.2 Methods 
2.2.1 Molecular analysis 
Methylation data were obtained using the Illumina Infinium HumanMethylation 450 
(450k) and Illumina Infinium MethylationEPIC arrays according to manufacturer’s 
instructions. The analyses were conducted by the Genomics and Proteomics Core Facility 
of the DKFZ, Heidelberg. Copy-number variation plots were generated from the 
Bioconductor package ‘conumee’ version 1.12.0.  
2.2.2 cDNA synthesis 
The following tumour IDs were used as starting material for cDNA synthesis of the 
respective candidate gene fusion: GBM1297 (PPP1CB:ALK), ICGC_PA82 (QKI:NTRK2). 1µl 
of RNA was mixed with 1 µl Oligo(dT) primers (500µg/ml) and 1µl dNTPs (10mM) from 
the SuperScript II reverse transcriptase kit and filled up with 9µl of nuclease-free water. 
This mixture was heated to 65°C for 5 minutes and briefly chilled on ice before adding 
4µl 5x First-Strand Buffer, 2µl 0.1M DTT and 1µl RNase OUT. This was then incubated at 
42°C for 2 minutes before adding 1µl SuperScript RT and two further incubation steps 
first at 42°C for 50 minutes and then at 70°C for 15 minutes. This served as a DNA 
template for the following polymerase chain reaction (PCR) in 2.2.4. 
For both FGFR1 (Fibroblast Growth Factor Receptor 1) mutations, no cDNA synthesis was 
required, because both were already present in the pcDNA3.1 vector, which was used as 
a DNA template for the PCR in the next step. 
2.2.3 ASAP cloning 
For the QKI:MYB fusion, no corresponding RNA was available from the patient, so 
therefore the most commonly found fusion sequence was taken from Bandopadhayay et 
al.204 and cloned using ASAP (Adaptable System for Assembly of multiplex Plasmids) 
cloning (Zuckermann et al. in preparation) with pre-prepared MYB and QKI clones from 
Dharmacon and the DKFZ Genomics & Proteomics Core Facility, respectively. A single 
cell smear from the glycerol stocks were plated onto LB-Ampicillin (MYB) and LB-
Kanamycin (QKI) agar plates and colonies were picked on the next day, which were 
incubated in LB-Ampicillin and LB-Kanamycin medium overnight at 37°C. DNA was 
isolated using QIAprep® Spin Miniprep kit according to manufacturer’s protocol. This 
was then used for a PCR reaction to amplify the DNA using the following setup: 
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PCR reaction: 
1µl  DNA (~10ng) 
1µl  dNTPs 
5µl  GC Buffer 
2µl  Primer mix (450µl H2O, 25µl forward and reverse primer each (100µM) 
0.5µl  Precisor DNA polymerase 
14.5µl H2O 
PCR setup: 
98°C - 5 min 
98°C - 30 sec 
57° - 30 sec 
72°C - 45 sec (QKI)/ 1 min (MYB) 
72°C - 10 min 
4°C - hold 
PCR purification was performed using QIAquick PCR purification kit before the following 
digestion and ligation reaction was set up as follows: 
1µl  XbaI 
1µl  NheI 
1µl  BsmBI 
1µl  Quick Ligase 
1µl  Fast Digest Buffer 
1µl Quick Ligase Buffer 
1µl  1:5 px330 (200ng) 
xµl  insert in 2:1 molar insert:vector ratio 
xµl  H2O 
 
 
 
x40 cycles 
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37°C - 20 sec 
37°C - 3 min 
16° - 4 min 
50°C - 5 min 
80°C - 5 min 
4°C - hold 
To cut non-circular DNA, a Plasmid Safe reaction was performed as follows and 
incubated at 37°C for 30 minutes: 
Plasmid Safe reaction: 
11µl  GGB product 
1µl  Plasmid safe Nuclease 
1.5µl  ATP 
1.5µl  Plasmid Safe Buffer 
2.2.4 Amplification of cDNA and digestion 
1µl of DNA from steps 2.2.2 and 2.2.3 DNA was used as a template for gene 
amplification in the following PCR reaction and setup: 
PCR reaction: 
1µl  DNA (~10ng) 
1µl  dNTPs 
5µl  GC Buffer 
2µl  Primer mix (450µl H2O, 25µl forward primer, 25µl reverse primer) 
0.5µl  Precisor DNA polymerase 
14.5µl H2O 
PCR purification was performed according to manufacturer’s instructions using the 
QIAquick PCR purification kit. For the RCAS cloning, the PCR product was then digested 
with the restriction enzymes NotI and ClaI in Cut Smart Buffer at 37°C for 1 hour, after 
which the cut product was run on a 1% Agarose gel at 120V for 50 minutes. The correct 
band size for the respective candidate gene was then cut out and the DNA was extracted 
using the QIAquick Gel Extraction kit according to manufacturer’s instructions. For the 
PT2K cloning, the purified PCR product was digested with EcoRI and XhoI in Fast Digest 
x26 cycles 
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Buffer at 37°C for 15 minutes and applied to a 1% Agarose gel, which was run for 50 
minutes at 120V. The correct band of the candidate gene’s corresponding size was also 
cut out here using the QIAquick Gel Extraction kit according to manufacturer’s 
instructions. The DNA concentrations of the extracted products were measured.  
2.2.5 Cloning into the RCAS vector 
The gel extracted insert with the NotI and ClaI overhangs was then ligated into the in-gel 
RCAS vector (preheated to 60°C) using the Takara ligation mixture. For that, 10µl of a 3:1 
molar ratio of insert to vector was added to 10µl Takara DNA ligation mix and incubated 
at 16°C for 30 minutes. 5µl of this ligation mix was then added to 25µl of One Shot 
TOP10 Chemically Competent E.coli bacterial solution and incubated on ice for 30 
minutes. This was followed by a heat shock step for 40 seconds in a 42°C warm water 
bath and 2 minutes on ice. 250µl of SOC medium was added to the transformation 
mixture, and 140µl of this was plated onto a pre-warmed Agar plate containing 
Ampicillin. Due to the vector containing an Ampicillin resistance gene, only bacteria 
containing the vector-DNA ligation will grow on the plate. The plate was incubated at 
37°C overnight and bacterial colonies were picked the next day and inoculated in 3ml LB-
Amp medium and again incubated overnight at 37°C on a rocking platform. 2ml of the 
bacterial solution was then used for isolation of the plasmid using the QIAprep® Spin 
Miniprep kit according to manufacturer’s protocol. A control digestion with ClaI and NotI 
was performed for 1 hour at 37°C in CutSmart Buffer and run on a 1% Agarose gel at 
120V for 30-60 minutes to check if both the RCAS vector (~11.7kB) and the insert are 
present. For the isolated DNA, which showed the correct bands on the gel, 80ng/µl in 
20µl was send to GATC Biotech (Konstanz, Germany) for Sanger sequencing. The 
resulting sequence was then checked with the sequence of the inserted DNA fragment 
using the Sequence Scanner software. If no or only silent mutations were present in the 
insert, 100µl of the remaining bacterial solution of the corresponding isolated DNA were 
inoculated in 200ml LB-Amp Medium and incubated overnight at 37°C on a rocking 
platform. The next morning, the plasmid was isolated using the Endofree Plasmid Maxi 
kit according to the manufacturer’s instructions. 
 
2. Materials & Methods 
45 
 
2.2.6 Cloning into the PT2K vector 
50ng of the PT2K vector were combined with a 3-fold molar excess of the cut DNA insert 
with XhoI and EcoRI overhangs using 2x Ligation Buffer, as well as the T4 DNA Ligase and 
mixed thoroughly. This mixture was incubated at room temperature for 5 minutes 
before bacterial transformation was performed as described in 2.2.5. The remaining 
steps are the same as in 2.2.5, apart from the control digestion, which was performed 
with EcoRI and XhoI. 
2.2.7 Transfection of DF-1 cells and p0 injection 
Ntv-a or XFM pairings were set up and the vaginal plug-positive date was recorded. Two 
weeks before the p0 injection, DF-1 cells were thawed and kept in DMEM + 10% FCS + 
1% Penicillin/Streptomycin (P/S) + 1% Glutamax at 5% CO2 at 39°C. Cells were split twice 
a week with Trypsin-EDTA in a 1:10 ratio. Four days before the calculated birth date, DF-
1 cells were plated at 2-3x105 cells/ T25 flask in 5ml DMEM as described above. The day 
after, the cells were transfected with the RCAS virus as follows: 4µg of the RCAS plasmid 
was incubated in 200µl of room-temperature Optimem and 10µl FuGene transfection 
reagent. After a 15-minute incubation time, this mixture was slowly added to the settled 
DF-1 cells, mixed well by gently moving the flask and placed back in the incubator. An 
RCAS-GFP plasmid was always run in parallel in a separate flask to check for transfection 
success. If these DF-1 cells express GFP on the day of injection, it can be assumed that 
the transfection also worked for the other plasmids assuming all steps were done the 
same way. 
On the day of birth, the transfected DF-1 cells were harvested using 10x Trypsin-EDTA 
and counted using the automated cell counter TC20™. 4x105 cells in 1µl were used for 
the p0 injection. The required amount of cells, depending on the size of the litter, was 
eluated in DMEM culture medium. The pups were taken out of the cage in a sterile hood 
and injected into the striatum with 1µl of the DF-1 cell solution using a 10µl Hamilton 
syringe (ga26s/51mm/pst2; Figure 11).  
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Figure 11. p0 injection into the striatum of a neonatal XFM mouse. A. Handling of the pup with correct 
positioning of the Hamilton syringe. The insertion angle should be 45° with an insertion depth of 2-3mm 
into the left hemisphere, B. The tip of the Hamilton syringe shows the point of injection. The red paint on 
the tip aids in judging the insertion depth, a third of the needle below the red mark was inserted into the 
mouse brain.  
After injection, the needle was very slowly drawn out of the head. No analgetics or 
anesthesia are needed, due to an absence of pain perception of the pups at this stage of 
life. After, the pups were placed back into the cage and covered by nesting material to 
override any foreign smell. Animals were observed until the mother took care of them 
again and weaned at 3 weeks after birth. Animals were separated according to sex and 
observed daily for symptoms of tumour growth. These experiments were carried out 
under the registered and approved animal protocols G-212/16 and G-238/12. 
2.2.8 In utero electroporation 
Before surgery, the injection needle and the plasmid solution had to be prepared. 
For the former, Borosilicate Glass Capillaries were pulled on the Micropipette Puller 
(Heat=560, Pull=150, Velocity=75, Time=250) and ground at a 30° angle to produce a 
sharp angled tip enabling injections into the embryonic brain without further harming it. 
The plasmid solution was prepared as follows: 
0.5µl Fast Green, 10x Phosphate Buffered Saline (PBS) was diluted to 1x PBS according to 
the final volume, 1mg/µl of PT2K-IRES-Luciferase containing the human influenza 
hemagglutinin (HA)-tagged gene of interest, the transposase vector and optionally, a 
guide RNA (gRNA) vector of either cdkn2a or p53. This was then made up to the total 
volume of ~10µl/pregnant mouse with water. Pregnant CD1 animals were generated at 
the Central Animal Facility of the DKFZ Heidelberg and the VP date was recorded. One 
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day before the in utero electroporation surgery, the animals were given the pain killer 
Metamizol in the drinking water at a concentration of 800mg/kg/day. At E14.5, the 
pregnant animals were anesthetized with 2% isoflurane p.i. and placed on a heating mat, 
on which they stayed for the whole duration of the surgical procedure. A small skin 
incision was made on the ventral side of the mouse followed by an incision of the 
peritoneum. The whole uterine horn was gently retrieved and placed onto the female’s 
belly (Figure 12A). Approximately 2µl of the plasmid solution was injected into the 
lateral ventricle of the embryos (Figure 12B) and subsequently electroporated with 
forceps-like electrodes at 33V for 5 pulses for 50ms (Figure 12C). After all embryos had 
been injected and electroporated, the uterine horn was placed back into the mother and 
both incisions were sewed back together (Figure 12D). The mouse was then placed back 
into the cage onto a heating mat and closely observed for the next 24 hours. Up to 48 
hours after surgery, animals received Metamizol in the drinking water at the same 
concentration mentioned above. 
 
Figure 12. In utero electroporation at E14.5; A. A skin and peritoneum incision are made after which the 
whole uterine horn is placed outside the belly. B. The prepared injection solution containing the PT2K-
IRES-Luciferase vector with HA-tagged candidate gene and Transposase vector and (where desired) a 
guide RNA is injected into the ventricle. C. The brain of the embryo is exposed to five, 50ms electric pulses 
of 33V each so that the injection solution penetrates the ventricular wall and can be taken up by the stem 
cells lining the ventricle. D. At the end of the surgery, the peritoneum and the skin incision are sewed back 
together and the mouse is monitored closely. 
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2.2.9 Luciferase imaging 
The luciferase gene on the PT2K vector serves the purpose to evaluate successful 
incorporation of the plasmid into the embryos’ brain, and to subsequently observe 
tumour growth in vivo. The animals, which successfully incorporated the plasmids, will 
show a positive luminescence signal when imaging around three days after birth. For 
that, the pups were placed into a 2% isoflurane chamber until asleep and injected with 
15mg/ml Luciferin at a volume of 10µl/1g of body weight. Seven minutes later, the pups 
were placed into the IVIS® Lumina LT Series III (PerkinElmer) and measured for three 
minutes. All positive pups were placed back into the cage with the mother, whereas all 
pups showing no luminescence signal were sacrificed by decapitation. 
2.2.10 FFPE tissue & Histological stainings 
After mouse brains were taken from the animal, they were placed in 10% formalin 
solution and kept at 4°C until further processing. For that, the brains were placed into 
formalin in the dehydration machine and underwent the following dehydrating steps 
over a period of 60 hours: 70% EtOH, 80% EtOH, 80% EtOH, 100% EtOH, 100% EtOH, 
xylene, xylene and finally two paraffin baths. The dehydrated mouse brain was then 
paraffin embedded into an embedding cassette.  
The blocks were cut at 3µm thickness, sections placed into a 42° C water bath, then onto 
microscope slides and dried overnight in a 37°C incubator. 
Haematoxylin & Eosin (H&E) staining was performed according to standard protocols. 
Slides were placed into two xylene baths of 15 minutes each followed by two 100% EtOH 
baths, one 95% EtOH, one 70% EtOH bath and one deionised water bath for 5 minutes 
each. Slides were stained in Haematoxylin for 1.5 minutes, cleared in tap water for up to 
5 minutes and rinsed in deionised water. All acidic and negatively charged substances 
(DNA/RNA) are now stained violet. The 1-minute Eosin bath that followed binds to 
positively charged amino acid chains and displays them in pink. The slide is then rinsed 
in deionised water and 70% EtOH followed by 5 minutes each in 95% EtOH and two 
100% EtOH baths and finally two xylene baths of 15 minutes each. The stained slides 
were covered with Eukitt mounting medium and a cover slip, and dried overnight. 
2. Materials & Methods 
49 
 
Immunohistochemistry (IHC) staining was performed with the LSAB+ Dako Real 
Detection kit with two prior steps of deparaffinisation and antigen retrieval. For the 
deparaffinisation and rehydration, the 3µm sections were placed into two xylene baths 
of 15 minutes each followed by 5 minutes each in 100% EtOH twice, 95% EtOH, 70% 
EtOH and distilled water. At the same time 10mM citrate buffer (pH6.0) is preheated in a 
steamer for 30 minutes into which the deparaffinised and rehydrated slides were placed 
for 40 minutes. The cuvette with the slides and citrate buffer was then taken out and 
cooled down at room-temperature for 20 minutes before washing the slides in distilled 
water for 1 minute and twice in TBS-T for 5 minutes. A 3% H2O2 solution (in TBS-T) was 
prepared and slides were incubated for 10 minutes to block endogenous peroxidase. 
This was followed by two washes in TBS-T, blocking with avidin, two more washes, 
blocking with biotin and two more washes before slides were covered with the primary 
antibody and incubated overnight in the dark at 4°C. Rabbit monoclonal anti-HA-tag (Cell 
Signaling Technology) was diluted 1:800 in antibody diluent from the kit. The antibody 
diluent alone served as a negative control. 
On the second day, the primary antibody was washed off in TBS-T three times for 5 
minutes, and slides were incubated in the DakoREAL biotinylated secondary antibody at 
room temperature for 15 minutes. Following this were two further washes in TBS-T for 5 
minutes each, an incubation of DakoREAL streptavidin peroxidase for 20 minutes at 
room temperature in the dark and two further washes in TBS-T for 5 minutes each. 
Detection of the secondary antibody was by a 1:50 dilution of DAB+Chromogen in HRP 
substrate buffer for 1 minute before placing the slides into deionised water. The nuclei 
were stained in Haematoxylin for 1 minute and excessive staining was washed off in tap 
water until clear. Slides were dehydrated again in increasing alcohol concentration baths 
of 70% for 15 seconds and 95% EtOH followed by two 100% EtOH baths for 5 minutes 
each and two xylene baths of 15 minutes each. Slides were covered in Eukitt mounting 
medium and a cover slip and dried overnight. 
2.2.11 Primary tumour cell culture 
After taking out the tumour bulk from the brain of the mouse, the tissue was 
mechanically dissociated into single cells immediately, filtered through a 40µm strainer, 
then cells were counted and seeded onto 10cm culture dishes. The cells were plated in 
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Neurobasal-A and DMEM/F-12 media containing 1% 1M HEPES Buffer Solution, 1% 
100mM Sodium Pyruvate MEM, 1% 10mM MEM Non-Essential Amino Acids Solution, 1% 
GlutaMAX and 1% Antibiotic-Antimycotic (now termed Base medium) supplemented 
with 2% B27, 2µg/ml Heparin Solution, 10ng/ml H-PDGF-AA, 20ng/ml Recombinant 
Human FGF-basic and 20ng/ml Recombinant Human EGF (now growth factor (GF) 
medium). Cells were grown as sphere cultures. For splitting, cells were dissociated with 
Accumax at 37°C for 5 minutes. 
2.2.12. Sequencing of the cdkn2a and p53 loci 
In order to verify that the CRISPR nuclease successfully and correctly cut at the gRNA site 
of the p53 and cdkn2a loci, DNA was isolated from tumour cell pellets and the respective 
loci were amplified in a PCR reaction. The product was then run on a 1.5% agarose gel 
from which it was isolated using the QIAquick Gel Extraction kit according to 
manufacturer’s instructions. 27.5ng of that was added to 1µl blunt pJET vector, 10µl 
reaction buffer and 1µl T4 DNA ligase and made up to 20µl with water. The vector was 
ligated to the PCR product for 5 minutes at room temperature and then transformed 
into electrocompetent E.coli according to standard protocol. The bacterial plates were 
incubated overnight at 37°C, from which colonies were picked the next day and 
amplified DNA was extracted the next day using QIAprep Spin Miniprep Kit according to 
manufacturer’s instructions. The product was then sent for sequencing at GATC Biotech 
and compared against the cdkn2a and p53 locus using Blast to check for Indels. 
2.2.13 Protein detection on Western blot 
For the phospho blots, 1x106 cells were plated on 10cm dishes and compounds 
(lorlatinib and crizotinib, with DMSO and GF medium as a negative control) were added 
to the dishes the next day and harvested 24 hours later. The harvest and following steps 
were all done on ice or at 4°C. Cell spheres were pelleted, washed in PBS + 1% 
protease/phosphatase inhibitor cocktail, pelleted again and snap frozen in liquid 
nitrogen first and then kept at -80°C. The cell pellet was dissolved in 1x NP-40 lysis buffer 
(2x NP-40 lysis buffer Tris HCl, NaCl and ddH2O) containing the same inhibitor cocktail 
mentioned above and incubated on ice for 45 minutes (vortexed from time to time). The 
cell pellet-lysis buffer mixture was then centrifuged at 13,000rpm for 10 minutes at 4°C 
before the supernatant was transferred to a new tube. A Bicinchoninic Acid (BCA) assay 
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was performed according to standard protocol to determine the protein concentration 
of each sample before denaturing in a NuPage sample buffer, ß-Mercaptoethanol and 1x 
lysis buffer mixture at 95°C for 5 minutes. 30 µg of the denatured samples were applied 
to 4-12% gradient NuPage Bis-Tris precast gels for protein electrophoresis and run at 
60V for 30 minutes and then for 1.5 hours at 130V. The split protein was then 
transferred to a PVDF membrane using the following setup: 
10 min  100mA 
10 min  200mA 
10 min  300mA 
10 min  400mA 
20 min  500mA 
10-60 min 50mA 
The membranes were then placed into a 5% BSA (Albumin Fraction V) or 5% milk 
blocking solution for 1 hour at room temperature and cut at ~35kDa and ~50kDa before 
the membranes were incubated with the primary antibodies at 4°C for 48 hours. The 
following primary antibodies were used: rabbit monoclonal anti-HA-tag (Cell Signaling 
Technology) 1:3000 in 5% BSA, rabbit polyclonal anti-ALK (Thermo Fisher Scientific) 
1:300 in 5% BSA, rabbit polyclonal anti-phospho-ALK (Cell Signalling Technologies) 
1:1000 in 5% BSA, rabbit polyclonal anti-cleaved Caspase-3 (Cell Signalling Technology) 
1:500 in 5% milk and mouse monoclonal anti-GAPDH (Millipore) 1:5000 in 5% BSA. 
48 hours later, the primary antibody was washed off in 1xTBS-T before the secondary 
antibody, goat polyclonal anti-Rabbit IgG-HRP or goat polyclonal anti-Mouse IgG-HRP 
were applied to the membrane in 1:2000 and 1:3000 dilutions, respectively in 5% BSA or 
5% milk depending on the primary antibody and incubated overnight at 4°C. Membranes 
were washed in TBS-T again, after which the proteins were detected using ECL Prime (p-
ALK) or ECL (all others) reagents for 1-15 minutes on a chemiluminescence imager (Intas) 
depending on the strength of their signal. 
For the non-phospho Western blots, cells were not treated with any phosphatase 
inhibitor compounds and were lysed using 1x lysis buffer (10x lysis buffer made from 
RIPA buffer and cOmplete™ Mini EDTA-free protease inhibitor cocktail tablets). Primary 
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antibody incubation was only overnight at 4°C and secondary antibody incubation for 1 
hour at room temperature. Another difference was that only 30µg of protein were 
loaded. The rest of the procedure stayed the same. 
2.2.14 Immunofluorescence cyto staining 
Immunofluorescence (IF) staining was performed to validate the purity of the tumour 
cells taken in culture to confirm that these cells really originate from the tumour 
initiated by in utero electroporation through the detection of the HA-tag with a 
fluorescent signal. Tumour cells were plated onto Lab-Tek II chamber slides at 2x104 cells 
per well in GF medium with 4% FCS and either left in culture for 72-96 hours depending 
on confluency or treated the next day with 400nM of lorlatinib.  
After incubation time, the medium was taken off and slides were washed with PBS and 
subsequently fixed in 1% PFA (in PBS) solution at room temperature for 10 minutes. 
Slides were washed twice with PBS before cells were permeabilised with 0.1% Triton-X-
100 in PBS for 10 minutes at room temperature. Three washes in PBS followed as well as 
antigen retrieval in hot citrate buffer for 20 minutes. Afterwards, slides were left in the 
buffer for 20 minutes to cool down before being washed in PBS again twice. Slides were 
then blocked in 10% normal donkey serum in PBS-T for one hour at room temperature. 
After blocking, cells were incubated in a 1:800 dilution of Rabbit anti-HA-tag antibody in 
PBS-T + 10% normal donkey serum overnight at 4°C. The negative control did not 
contain the antibody. 
On the next day, slides were washed in PBS three times before the secondary antibody 
Alexa Fluor® 568 donkey anti-rabbit IgG was added in a 1:400 dilution in PBS-T for 1 hour 
at room temperature. Slides were then washed for 10 minutes each in TBS-T three 
times, in PBS once and in water once. DAPI Fluoromount-G® mounting medium was 
added onto the slide, which was then covered with a cover slip and dried overnight in 
the dark before representative images were taken on the fluorescent microscope. 
2.2.15 In vitro inhibitor testing 
All drugs were purchased from Selleck Chemicals and diluted in DMSO to either a 10mM 
or 1mM stock, which were stored at -80°C. Primary sphere culture cells were plated at 
1x104 cells/well in 80µl GF medium medium/well in 96-well plates. Triplicates per drug 
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concentration were added 24 hours after seeding the cells in 20µl. The drug 
concentrations ranged between 30µM and 0.01nM depending on the drug. 
Corresponding DMSO concentrations were plated to which the treated wells were 
normalized. ALK-specific inhibitors included: crizotinib, ceritinib, alectinib and lorlatinib. 
Entrectinib was used as an NTRK inhibitor, and has been shown to function as a TrkA, 
TrkB, TrkC, ROS1 and ALK inhibitor. Infigratinib (BGJ398) is a FGFR1/2/3-specific inhibitor 
and was used as a negative control for the specificity of the ALK and NTRK inhibitors on 
PPP1CB:ALK-fused and QKI:NTRK-fused cells, respectively. 
The CellTiter-Glo readout was conducted 72 hours after drugs were added to the cells. 
For that 50µl of CellTiter-Glo substrate were added to each well using a multichannel 
pipette, plates were incubated for 15 minutes whilst shaking in the dark. After that time, 
the viability of the cells was measured in the microplate reader Mithras LB940. The 
respective DMSO control value was subtracted from the drug’s value to normalize the 
readout. The IC50 curves show the mean ± SD of the triplicates per condition measured. 
2.2.16 Annexin V flow cytometry analysis 
PPP1CB:ALK tumour spheres were plated at 3x105 cells in 3 ml per well in 6-well 
suspension plates and incubated overnight. The next day, three wells each were treated 
with the following substances: non-treated (GF medium), DMSO control, crizotinib and 
lorlatinib at an end concentration of 400nM (or 0.004% for the DMSO control). 72 hours 
later, cells were harvested by pipetting up and down, centrifuged and washed in cold 
PBS. Staining with FITC annexin V and Propidium Iodide (PI) was performed according to 
manufacturer’s instructions (Dead Cell Apoptosis Kit, Life Technologies). Flow cytometry 
analysis was perfomed on the FACS Canto, where 100,000 events were counted and 
recorded and subsequently analysed on the FACS Diva software.  
2.2.17 Cell cycle analysis 
Cell cycle analysis was performed using the Propidium Iodide Flow Cytometry kit from 
abcam. PPP1CB:ALK tumour spheres were plated at 3x105 cells in 3 ml per well in 6-well 
suspension plates and incubated overnight. The next day, three wells each were treated 
with the following substances: non-treated (GF medium), DMSO control, crizotinib and 
lorlatinib at an end concentration of 400nM (or 0.004% for the DMSO control). 72 hours 
later, cells were harvested by pipetting up and down, centrifuged at 500 x g for 5 
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minutes and washed in 1x PBS before being centrifuged again. The supernatant was 
discarded and cells were fixed in 66% EtOH for 2 hours at 4°C. Cells were equilibrated to 
room temperature before being pelleted, washed in 1x PBS and pelleted again. Pellets 
were resuspended in 200µl 1x Propidium Iodide + RNase staining solution and incubated 
in the dark at 37°C for 20-30 minutes. Cells were then placed on ice and ready for flow 
cytometry analysis. This was performed on the FACS Canto, where 100,000 events were 
counted and recorded and subsequently analysed on the FACS Diva software. 
2.2.18 Intracranial injection 
To test the effectiveness of ALK inhibition in vivo, intracranial injection of 6 week old 
CD1 mice with mouse PPP1CB:ALK tumour cells was performed. For that, mice were 
given 800mg/kg/day Metamizol in the drinking water 24 hours before the surgery. On 
the day of injection, mice were anesthetised by inhalation with 2% isoflurane and placed 
onto a heat mat and into the stereotactic frame. Bepanthen was put onto the eyes to 
avoid blindness, as well as onto the head to make the hairs sticky so that they do not 
enter the open wound. A small incision was made, followed by a hole slowly drilled into 
the skull at the point indicated in Figure 13. 4µl of the tumour cells were drawn up in a 
Hamilton syringe, which was placed into the stereotactic frame. The needle was then 
inserted into the hole made and the tumour cells were slowly injected over two 
minutes. The Hamilton needle was then slowly pulled out of the hole to avoid negative 
pressure and the cut was glued together with tissue glue. The mouse was placed back 
into the cage and observed closely for the next 24 hours.  
 
Figure 13. Dorsal view onto mouse skull with blood vessels and injection area for injections into the 
striatum indicated. 
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2.2.19 In vivo inhibitor testing 
The animal protocol under which the inhibitor testing was conducted (G-168/17) was 
approved by the Regierungspräsidium Karlsruhe before starting the experiment. The 
chosen inhibitor was lorlatinib based on the in vitro results, as well as HCl and 
Temozolomide as vehicle control and standard-of-care, respectively. The doses and 
treatment regime of the first two drugs were adapted from Infarinato et al.205 and 
Temozolomide was administered according to the suggested dose on the suppliers 
website (http://www.selleckchem.com/products/Methazolastone.html). Animals were 
weighed three times a week and any abnormal behaviour or symptoms were recorded 
and the animals were sacrificed when they reached a critical status. Half of the mouse 
brain was then formalin-fixed and paraffin embedded and the other half was snap 
frozen in liquid nitrogen and frozen at -80°C for further analysis. 
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3. Results 
3.1 Proof of concept animal model 
Before testing drugs or specific targeted inhibitors in clinical trials in humans, their 
effectiveness and safety needs to be pre-clinically tested in vivo. In order to do that, 
respective animal models of recurrent somatic mutations found in the paediatric 
patients’ tumours need to be established and validated. Here, I used the techniques of in 
utero electroporation and p0 injection using the RCAS/t-va system to generate tumour 
bearing mouse models aiming to recapitulate the appearance of the paediatric tumours 
as close to the human situation as possible. The main focus of this work was on the 
PPP1CB:ALK fusion, however other candidate genes were also tested to support the 
more general applicability of the pre-clinical pipeline outlined here. 
3.1.1 Successful cloning of recurrent paediatric candidate genes 
After extraction of RNA, synthesis of cDNA and cloning of the fusion gene cDNA into the 
RCAS and PT2K vectors, the plasmids were sequenced using Sanger sequencing at GATC 
Biotech. The PPP1CB:ALK fusion was correctly cloned into the vectors with three known 
SNPs at protein positions 1461, 1491 and 1529 compared with the reference sequence 
(data not shown). To test if the RCAS vector is working sufficiently and expressing the 
correct fusion/mutation proteins, DF-1 chicken cells were transfected with 4µg of the 
plasmid. During cloning of the human PPP1CB:ALK sequence, the sequence for the 
human influenza hemagglutinin (HA) glycoprotein was added to the C-terminus of the 
fusion gene. This enables easy detection of the desired fusion gene by staining against 
the HA-tag in immunohistochemistry or immunofluorescence staining or by Western 
blotting. After three days, pellets of the cells were harvested and run on a Western blot 
against the HA-tag to confirm that the tagged protein of interest is present (Figure 14). 
The harvested DF-1 cells expressed the respective protein of the transfected plasmids 
for all HA-tagged samples. The red arrows indicate the detected band of the desired 
proteins, which were as follows: PPP1CB:ALK- 85kDa, QKI:NTRK2- 76kDa, MYB:QKI- 
64kDa and FGFR1mut- 93kDa. All proteins ran at ~10-15kDa higher than expected based 
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on calculated molecular weight. RCAS_GFP, which does not contain a HA-tag, serves as a 
negative control and was therefore not detected on the blot.  
 
Figure 14. Western blot against HA detecting cloned constructs of candidate genes. DF-1 cells were 
transfected with the cloned constructs using FuGene. This Western blot was performed as described in 
2.2.13 and stained against HA-tag and GAPDH as a loading control (~37kDa). The membrane was exposed 
to ECL detection reagent for 30 seconds. The RCAS_GFP vector serves as a negative control, because it 
does not have the HA-tag fused to it unlike all the other constructs, which all show a positive signal. This 
means that all vectors were successfully cloned and express the desired protein.  
 
3.1.2 ALK fusion-containing mice successfully develop tumours from 29 days after in 
utero electroporation  
To generate tumours bearing the desired PPP1CB:ALK fusion, one prenatal and one 
neonatal method of somatic gene transfer were applied to test the oncogenicity of this 
fusion in vivo. The two experimental methods of inducing PPP1CB:ALK-positive tumours 
in vivo gave different results. The p0 injected XFM animals did not develop any tumours, 
but rather died from other symptoms at an average age of 195 days (n=19) due to the 
constitutive Cdkn2a (cyclin-dependent kinase inhibitor 2A) knock-out of the mice (Figure 
15B). 
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Therefore, all of the following results are based on tumours derived from in utero 
electroporated CD1 mice (Figure 15A). On average about 30% of all electroporated 
animals survive the in utero electroporation procedure, out of which half contain the 
inserted transgene, shown by a positive luciferase signal detected through the IVIS 
device three days after birth. Tumours arose in almost 100% of positive luciferase signal 
pups. Tumours harbouring PPP1CB:ALK in combination with either sgp53 or sgcdkn2a 
developed quicker than tumours just containing the fusion gene. On average, they 
survived 137 (wt; n=2), 55 (sgcdkn2a; n=4) and 35 (sgp53; n=10) days after birth until 
tumour-related symptoms developed (Figure 15, Table 3). Symptoms included reduced 
locomotion, hunched back and rounded skull.  
This high penetrance and fast tumour development of the sgcdkn2a and sgp53 
combination with PPP1CB:ALK makes in utero electroporation a good method for mouse 
model development in this setting. 
 
Figure 15. PPP1CB:ALK tumours from in utero electroporation. A. CD1 mouse brain showing a 
PPP1CB:ALK + sgp53 bearing tumour within the striatum at 39 days after birth. This mouse was sacrificed, 
because it developed symptoms due to the tumour growth. B. Kaplan-Meier survival curve of animals 
injected with PPP1CB:ALK at either E14.5 or p0. The latter did not develop tumours, whereas animals from 
in utero electroporation did. These developed quicker when combined with a sgRNA against either cdkn2a 
or p53. Only two of 19 XFM mice harboured a tumour and the others all died on non-brain tumour related 
symptoms indicated by the small vertical lines across the horizontal one.  
Table 3 is an overview of all PPP1CB:ALK tumours generated from in utero 
electroporation either alone or in combination with a second hit against the tumour 
suppressors cdkn2a or p53. Tumour cells were not taken into culture from all of these 
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tumours, but the ones from which cells are available in culture and further validation 
experiments were obtained are marked with an asterisk. 
Table 3. Listing of tumour-bearing mice by their ID and the corresponding genetic aberration and 
latency. 
* indicates that the tumour cells were taken into culture and further analyses were done 
ID Candidate gene Second hit Latency (days) 
BI#169* PPP1CB:ALK sgcdkn2a 45 
BI#386* PPP1CB:ALK sgcdkn2a 45 
BI#292 PPP1CB:ALK sgcdkn2a 52 
BI#305 PPP1CB:ALK sgcdkn2a 78 
BI#357 PPP1CB:ALK sgp53 24 
BI#361 PPP1CB:ALK sgp53 28 
BI#362 PPP1CB:ALK sgp53 28 
BI#190* PPP1CB:ALK sgp53 30 
BI#191* PPP1CB:ALK sgp53 32 
BI#272 PPP1CB:ALK sgp53 33 
BI#363 PPP1CB:ALK sgp53 39 
BI#365 PPP1CB:ALK sgp53 41 
BI#281 PPP1CB:ALK sgp53 46 
BI#283* PPP1CB:ALK sgp53 52 
BI#207 PPP1CB:ALK - 112 
BI#271* PPP1CB:ALK - 162 
 
3.1.3 Tumour cells in vitro 
Table 3 lists the mice, which successfully developed a tumour from in utero 
electroporation with the PPP1CB:ALK fusion alone or in combination with a suppressor 
knock-out of p53 or cdkn2a. The asterisk indicates the cases from which cells from the 
tumour bulk were taken into culture. The tumour tissue was dissociated into single cells 
mechanically and then filtered before cells were plated into 10cm dishes. Cells were 
kept as sphere cultures in non-attachment dishes where they formed spheres nicely 
3. Results 
61 
 
(Figure 16). Spheres had to be split and dissociated into single cells every 3-4 days. Cells 
maintained their sphere forming ability for at least 20 passages. 
 
Figure 16. BI#283 spheres in culture. Cells are kept in non-attachment dishes at 37°C with 5% CO2 in 
growth factor medium. Scale bar: 200µm. 
3.1.4 PPP1CB:ALK model characteristics 
The presence of the HA-tag is a valuable tool to detect the fusion protein not only on 
Western blot, as already seen in Figure 14, but also in IHC and IF staining. This 
characteristic was utilised to show that the tumours in the mice are a direct result from 
the in utero electroporated oncogenic plasmids. 
Figure 17 shows the formalin-fixed paraffin-embedded (FFPE) mouse brains stained for 
H&E and the corresponding IHC staining against the HA-tag. In all of the tumours, the 
observed tumour mass in the H&E staining unambiguously corresponds to the positive 
staining of the IHC (Figure 17A). IHC staining of the mouse brains recapitulates the ALK-
positive human tumours by morphology nicely as assessed by two independent 
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experienced neuropathologists (Prof. Dr. David Capper and Prof. Dr. David Ellison). The 
fusion was not only detectable in the tissue sections, but also in the tumour cells taken 
into culture. This Western blot (Figure 17B) was an important step in defining the origin 
of the tumour and confirming that the sphere-forming cells cultured from the tumours 
are truly PPP1CB:ALK fused tumour cells developed from in utero electroporation, 
making them suitable for further experiments. 30µg of protein were loaded onto the 
protein gel to be able to compare relative expression of the fusion protein between the 
different primary cell cultures. Looking at Figure 17, BI#169 and BI#271 seem to have a 
lower protein expression of the HA-tag, but when taking the intensity of the GAPDH 
band in consideration, this is only true for BI#271 after all. This shows lower expression 
of the PPP1CB:ALK fusion protein compared to the other five primary cell cultures. 
However, the exposure time in this Western blot figure is relatively short (60 seconds), 
indicating that the absolute expression of the protein is high in all of these primary cells. 
Cells from HD-MB03 served as a negative control not expressing the HA-tag to make 
sure that the primary antibody is specifically only detecting the HA-tag. 
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Figure 17. Detection of the fusion protein by H&E and IHC staining on FFPE mouse tissue and Western 
blot from in vitro tumour cells. A. H&E staining and the corresponding IHC staining against the HA-tag 
clearly show that the observed tumour mass in the former, nicely correspond to the brown staining in the 
latter. The close up images are of 40x magnification and the scale bar is 100µm. B. Detection of 30µg of 
the fusion-HA-tag protein on Western blot. The detected bands all ran at ~95kDa, which is about 10kDa 
bigger than the theoretical protein size calculated. The protein was detected using ECL detection reagents. 
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The next step was to test if the tumour cells not only express the HA-tag and therefore 
the PPP1CB:ALK fusion, but also contain a dysfunctional second hit of either p53 or 
cdkn2a as expected (Figure 18). For this purpose, DNA was extracted from the primary 
cell cultures, a PCR of the cdkn2a or p53 locus was performed and that product was then 
cloned into the pJET vector, which then underwent Sanger sequencing. Figure 18 depicts 
the results of the sequenced bacterial colonies. As expected, BI#271 cells 
(electroporated with the PPP1CB:ALK fusion alone) show intact p53 and cdkn2a loci, 
confirming that no gRNA was electroporated in addition to the fusion gene. Both of the 
PPP1CB:ALK + sgcdkn2a primary cell cultures (BI#169 and BI#386) and BI#283 
(PPP1CB:ALK + sgp53) only showed one inserted base (Adenine or Thymine) in all 
sequenced colonies at the position where the CRISPR nuclease is supposed to cut, 
thereby inducing a frame shift mutation resulting in a non-functional protein. BI#191 
contains a one base insertion in most of the colonies sequenced, however it also shows 
a 245 base deletion after the site where the nuclease is supposed to cut in three cases. 
BI#190 is the most varied of all primary cell cultures, because it shows one (n=3) or two 
(n=1) base insertions, a 169 base deletion (n=1) or no cut (n=4) at the CRISPR target site. 
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Figure 18. Testing the effectiveness of the gRNA in the primary tumour cell cultures. BI#271, which are 
cells from a mouse not electroporated with a gRNA, show intact p53 and cdkn2a loci. Both PPP1CB:ALK 
fusion + sgcdkn2a primary tumour cell cultures show an insertion of an Adenine or Thymine base at the 
position where the DNA was supposed to be cut. This frame shift mutation results in a non-functional 
cdkn2a loci, which contributes to the tumourgenicity of the cells resulting in a faster tumour growth than 
just the PPP1CB:ALK fused cells as seen in Figure 15. The gRNA against p53 seems to result in more 
heterogenous tumour cells with one or two base pairs inserted, or a series of bases being deleted. In four 
colonies of BI#190, no cut was detected. The green bar represents the cdkn2a locus and the blue one the 
p53 locus. bp = base pair 
Furthermore, the cells in culture were also immunofluorescently stained against the HA-
tag to define the percentage of PPP1CB:ALK-positive cells in culture. This analysis 
confirmed that nearly 100% of cells in culture are ALK fusion positive tumour cells 
(Figure 19). This remained true for the surviving cells after treatment with lorlatinib 
(concentrations according to Figure 20 shows that the first line inhibitor crizotinib 
performs worst of all tested ALK inhibitors in vitro in the PPP1CB:ALK-fused cells with 
either of the CRISPR gRNAs against cdkn2a and p53 (BI#169, BI#190, BI#191, BI#283, 
BI#386). Cells show a better response to second line ALK inhibitors ceritinib and 
alectinib, as well as the combined NTRK and ALK inhibitor entrectinib, all developed later 
than crizotinib and therefore showing more specific targeting. Nevertheless, the latest 
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developed inhibitor, lorlatinib, performs best in terms of the dose response with low 
IC50 values ranging from 0.35-1.24nM. These values correspond to achievable 
concentrations that can be administered in patients in the clinic206. The FGFR1 
inhibitor, BGJ398 (infigratinib) is ineffective against ALK-positive cells, showing the 
specificity of the ALK inhibitors against cells harbouring this aberration. It also becomes 
clear that for essentially none of the tumour cell cultures do any of the drugs give a 
100% viability drop in response to treatment. This may be due either to a small 
proportion of the cells being resistant to treatment, which are therefore still 
metabolically active (which the CellTiter-Glo assay is detecting), or it could indicate that 
a proportion of the cells respond rather with a stop of proliferation (cytostatic) than by 
undergoing cell death (cytotoxic). This response however might shift upon s shorter or 
longer exposure time, which will need to be tested. 
Looking at Figure 20, it also becomes clear that the drug response curves of the primary 
cell culture from the tumour of just the PPP1CB:ALK fusion (BI#271) all show (nearly) 
100% response at the 2mM or 30µM concentration. Lorlatinib, however, does not seem 
to have an effect on these tumour cells with a high mean IC50 value of 11nM from the 
two replicates. This shows that the ALK inhibitors are potent to ALK-positive cells in 
combination with a tumour suppressor knock-out. 
After having determined the mean IC50 values of the three different primary tumour cell 
culture combinations, further tests were conducted to investigate what the ALK 
inhibitors are actually doing to the cells to explain the decreased viability of tumour cells 
being treated and the IC50 curves not reaching 0% in the majority of primary cell 
cultures in Figure 20.  
The mean of the IC50 values from the duplicates of the experiment were calculated and 
used as the basis for the drug concentrations for the flow cytometric and Western blot 
analysis. Table 4 indicates the IC50 values used for lorlatinib and crizotinib. The DMSO 
control concentrations are based on the lorlatinib concentrations. All lorlatinib 
concentrations are below 1.4nM (mean 0.76nM), which none of the other inhibitors 
come close to. The second best ALK inhibitor is alectinib with a mean IC50 of 3.3nM. 
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Table 4; data not shown), indicating no enrichment for e.g. drug-resistant stromal cells 
accounting for this surviving population. DAPI is stained in blue and the HA-tagged cells 
are shown in red. Images of the cells after treatment are not shown, since they were 
essentially identical to those displayed in Figure 19. The negative controls all just show 
DAPI staining and no specific staining of the Alexa Fluor dye, which is why they are not 
shown here. 
 
Figure 19. Representative immunofluorescence images of mouse extracted tumour cells in vitro stained 
against HA-tag bound to Alexa Fluor® 568. The top left image (BI#271) shows primary tumour cells from a 
PPP1CB:ALK fused only tumour, whereas the two images below that (BI#169 and BI#386) and the 
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complete right column images (BI190, BI#191 and BI#283) show ALK fused cells with sgcdkn2a and sgp53, 
respectively. In all representative images, almost 100% of cells are positive for the HA-tag indicating that 
the tumour cell culture is of high purity. Scale bar: 50µm. 
3.2 Comparison of different ALK-specific inhibitors 
After having tested the identity and purity of the cells taken into culture from the 
murine tumours, the next logical step was to test commercially available ALK-specific 
inhibitors on these ALK-fused cells to comment on their effectiveness and mechanism of 
action. In recent years, ALK inhibitor development has made great progress. From 
crizotinib, a first line ALK inhibitor, through alectinib and ceritinib showing effectiveness 
against crizotinib-resistant tumours to lorlatinib being an even more potent third line 
inhibitor. I therefore hypothesised that the latter inhibitor would give the most effective 
results in inhibiting ALK-positive tumour cells in vitro. 
3.2.1 Lorlatinib inhibits growth of ALK-fused primary cell cultures on average at 56-fold 
lower concentrations than crizotinib 
After confirming the true PPP1CB:ALK identity of the tumour cells and that the models 
recapitulate features of their human counterparts, the next step was to initiate pre-
clinical drug testing in vitro prior to going back into the mouse to do the same therefor in 
vivo confirmation. 
CellTiter-Glo is a luminescence-based viability assay measuring ATP to determine the 
number of viable cells in culture after treatment with chemotherapeutic agents, for 
example. It is based on the amount of ATP present, only found in live cells. Dead cells 
lose their membrane integrity and with this the ability to produce ATP. The 
luminescence signal intensity is therefore proportional to the number of metabolically 
active cells.  
Figure 20 shows one representative IC50 graph (experiment performed in duplicate) of 
each of the primary cell culture derived from the murine tumours marked with an 
asterisk listed in Table 3. Cells were plated at a density of 1x104 cells/well in a 96-well, 
white, clear bottom plate and after 24 hours, four different ALK-specific inhibitors 
(ceritinib, crizotinib, lorlatinib and alectinib) together with an FGFR1-specific inhibitor 
(BGJ398) and an NTRK/ALK inhibitor (entrectinib) were added in eight different 
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concentrations ranging from 0.01nm-30µM together with the corresponding DMSO 
concentrations. After a further 72 hours, CellTiter-Glo substrate was added and the 
luminescence of the treated cells was measured using a Mithras plate reader. From the 
generated data, the IC50 curves below were calculated using the GraphPad Prism 
software. 
 
Figure 20. IC50 curves of ALK-fusion cells treated with first, second and third line inhibitors, as well as 
NTRK- and FGFR1-specific inhibitors. The concentrations indicated next to the graphs, resemble the IC50 
value of that compound on those cells. In all but one primary cell culture (BI#271), lorlatinib performs best 
with IC50 values between 0.35 and 1.24nM. Cells were treated with the drugs for 72 hours. 
Figure 20 shows that the first line inhibitor crizotinib performs worst of all tested ALK 
inhibitors in vitro in the PPP1CB:ALK-fused cells with either of the CRISPR gRNAs against 
cdkn2a and p53 (BI#169, BI#190, BI#191, BI#283, BI#386). Cells show a better response 
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to second line ALK inhibitors ceritinib and alectinib, as well as the combined NTRK and 
ALK inhibitor entrectinib, all developed later than crizotinib and therefore showing more 
specific targeting. Nevertheless, the latest developed inhibitor, lorlatinib, performs best 
in terms of the dose response with low IC50 values ranging from 0.35-1.24nM. These 
values correspond to achievable concentrations that can be administered in patients in 
the clinic206. The FGFR1 inhibitor, BGJ398 (infigratinib) is ineffective against ALK-positive 
cells, showing the specificity of the ALK inhibitors against cells harbouring this 
aberration. It also becomes clear that for essentially none of the tumour cell cultures do 
any of the drugs give a 100% viability drop in response to treatment. This may be due 
either to a small proportion of the cells being resistant to treatment, which are 
therefore still metabolically active (which the CellTiter-Glo assay is detecting), or it could 
indicate that a proportion of the cells respond rather with a stop of proliferation 
(cytostatic) than by undergoing cell death (cytotoxic). This response however might shift 
upon s shorter or longer exposure time, which will need to be tested. 
Looking at Figure 20, it also becomes clear that the drug response curves of the primary 
cell culture from the tumour of just the PPP1CB:ALK fusion (BI#271) all show (nearly) 
100% response at the 2mM or 30µM concentration. Lorlatinib, however, does not seem 
to have an effect on these tumour cells with a high mean IC50 value of 11nM from the 
two replicates. This shows that the ALK inhibitors are potent to ALK-positive cells in 
combination with a tumour suppressor knock-out. 
After having determined the mean IC50 values of the three different primary tumour cell 
culture combinations, further tests were conducted to investigate what the ALK 
inhibitors are actually doing to the cells to explain the decreased viability of tumour cells 
being treated and the IC50 curves not reaching 0% in the majority of primary cell 
cultures in Figure 20.  
The mean of the IC50 values from the duplicates of the experiment were calculated and 
used as the basis for the drug concentrations for the flow cytometric and Western blot 
analysis. Table 4 indicates the IC50 values used for lorlatinib and crizotinib. The DMSO 
control concentrations are based on the lorlatinib concentrations. All lorlatinib 
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concentrations are below 1.4nM (mean 0.76nM), which none of the other inhibitors 
come close to. The second best ALK inhibitor is alectinib with a mean IC50 of 3.3nM. 
Table 4. Mean IC50 concentrations of lorlatinib and crizotinib as assessed by CellTiter-Glo analysis used 
for the drug treatment of cells for Western blot, Immunofluorescence and Annexin V staining, and cell 
cycle analysis. 
Primary cells Lorlatinib concentration Crizotinib concentration 
BI#169 0.9nM 28nM 
BI#190 0.6nM 32nM 
BI#191 1.3nM 66nM 
BI#283 0.5nM 48nM 
BI#386 0.5nM 24nM 
 
3.2.2 ALK inhibitors effectively diminish pALK signal in vitro 
Using the IC50 concentrations calculated in Table 4, BI#169 and BI#283 cells (harbouring 
PPP1CB:ALK with sgcdkn2a or sgp53, respectively) were treated with either normal GF 
medium as a negative control, DMSO, crizotinib or lorlatinib to evaluate the abilities of 
the ALK inhibitors to decrease excessive downstream signalling via the ALK receptor 
(indicated by receptor phosphorylation).  
Six-hour treatment of BI#169 and BI#283 with 28/48nM crizotinib and 0.9/0.5nM 
lorlatinib decreased the p-ALK signal and thus likely also downstream signalling. There is 
no difference seen in total ALK protein. Figure 21 shows that the apoptosis pathway is 
activated upon ALK inhibitor treatment by increased cleaved Caspase 3 signal compared 
to the non-treated and DMSO controls. High centrifugation of the treated cells was used 
in order to also pellet dead cells, which can then be detected on the Western blot.  
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Figure 21. Western blot of BI#169 and BI#283 treated cells in vitro stained against p-ALK, total ALK and 
cleaved Caspase 3. Upon ALK inhibitor treatment, p-ALK reduces in signal strength and cleaved Caspase 3 
increases in both primary cell cultures (BI#169 and BI#283). Total ALK signal stays the same. 60µg of 
protein was loaded. For the detection, ECL prime (for p-ALK and cleaved Caspase 3) or ECL (for total ALK 
and GAPDH) detection reagents were used. The membranes were developed for 30 seconds each. 
3.2.3 ALK inhibitors lead to DNA fragmentation 
Knowing that tumour cells show a decreased viability after ALK inhibitor treatment, it 
was of interest to see how this links to the stage of the cell cycle the treated and control 
cells are in. For that, flow cytometric analysis was performed using propidium iodide (PI) 
as a staining agent on tumour cells treated with crizotinib and lorlatinib at the calculated 
mean IC50 concentrations. PI is a stoichiometric dye, meaning it will bind to the 
proportion of DNA present in a cell. That way the cell cycle stages can be differentiated 
based on the premise that cells in G1 have half the amount of DNA than cells in G2, 
whereas cells currently in S-phase show an intermediate DNA amount. Cells residing in 
the sub G1 stage were also expected, because the CellTiter-Glo analysis revealed 
dying/dead cells after inhibitor treatment. The Sub G1 stage shows DNA fragmentation, 
a sign of apoptosis or necrosis. The number of cells in this stage increased upon 
treatment with crizotinib and lorlatinib, with more crizotinib-treated cells showing DNA 
fragmentation compared with lorlatinib-treated cells (Figure 22). 
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Figure 22. Cell cycle analysis of treated tumour cells in vitro. A. Representative flow cytometric cell cycle 
graph of BI#169 cells treated with DMSO, crizotinib and lorlatinib. B. Representative flow cytometric cell 
cycle graph of BI#283 cells treated with DMSO, crizotinib and lorlatinib. Drug treatment increases the 
fraction of cells in the Sub G1 phase, and decreases cells residing in G0/1 and G2/M. C. Graphical 
representation of the cell cycle stages in BI#169 cells based on the mean of the duplicated experiment. D. 
Graphical representation of the cell cycle stages in BI#283 cells based on the mean of the duplicated 
experiment. The asterisk (*) shows a significant difference of <0.05 between treatment with the ALK 
inhibitor crizotinib compared to the DMSO control. The numbers indicated within the bars indicate the 
mean percentage of cells in that phase taken from the duplicated experiment. 
BI#283 cells show a smaller proportion of cells in G0/1 phase after treatment compared 
to BI#169 cells, this might be due to differential effects of the deletion of p53 in the 
former cells compared with cdkn2a loss in the latter.  
3.2.4 ALK-specific inhibitor treatment drives cells into apoptosis and necrosis 
Knowing that the inhibitors result in fragmented DNA, it was important to evaluate 
further what effects crizotinib and lorlatinib have on the ALK-positive tumour cells in 
vitro. Therefore, an apoptosis assay was performed to distinguish between early and 
late apoptosis, and necrosis. Programmed cell death (apoptosis) is a naturally occurring 
process in living organisms to remove unwanted cells207 and can easily be analysed with 
flow cytometry with the use of fluorochrome-labeled Annexin V. Annexin V is a Ca2+-
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dependent phospholipid-binding protein with a high affinity for phosphatidylserine (PS). 
PS is translocated from the inner side of the plasma membrane to the surface as one of 
the earlier events of apoptosis. This exposes PS to the external cellular environment 
ready to be detected by Annexin V208-210, which is bound to the fluorochrome FITC 
responsible for the fluorescence signal detected on the flow cytometer.  
 
Figure 23. Flow cytometric Annexin V assay. A. FACS plot of BI#169 (PPP1CB:ALK + sgcdkn2a) cells treated 
with DMSO, crizotinib and lorlatinib (from top to bottom). B. FACS plot of BI#283 (PPP1CB:ALK + sgp53) 
cells treated with DMSO, crizotinib and lorlatinib (from top to bottom).C. and D. Graphical depiction of A 
and B. Error bars are not shown, since the experiment was repeated only twice with three pooled samples 
each. 
When looking at Figure 23 above, a difference in live/apoptotic status of the differently 
treated cells can be seen. The bar charts in Figure 23C and D graphically present what is 
seen in A and B. The colour code at the bottom shows DMSO bars in blue, crizotinib in 
orange and lorlatinib in grey.  
Upon crizotinib treatment, cells mostly move from the fourth quadrant (live cells) to the 
third and second quadrant (early apoptotic and late apoptotic cells, respectively). 
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Crizotinib-treated BI#169 cells reside mostly in early and late apopotosis compared with 
lorlatinib-treated cells, which are mostly late apoptotic and necrotic. Lorlatinib 
treatment drives a higher proportion of BI#169 cells into necrosis compared to cells 
under crizotinib treatment.  
BI#283 cells seem to have a higher proportion of cells (for both ALK inhibitors) in the 
early apoptosis and necrosis stages compared to BI#169 cells, which is most likely due to 
the missing p53 tumour suppressor gene. With p53 being disrupted in BI#283 cells, they 
likely go into necrosis faster and in greater quantities, with a relative ‘bypass’ of 
apoptosis. 
These results can give the impression that crizotinib has a stronger and better apoptotic 
effect on the cells, however one needs to keep in mind that for both drugs, the IC50 
values calculated in Table 4 from Figure 20 were used in order to make a mechanistic 
comparison. Thus, a much lower overall concentration of lorlatinib is able to achieve 
approximately the same effect as crizotinib. Judging from the IC50 curves, one can 
predict that lorlatinib will have a stronger effect on the cell cycle and apoptosis than 
crizotinib if both are applied at the same concentration.  
Overall, one can conclude that both ALK inhibitors successfully drive cells into apoptosis, 
with a portion of cells being necrotic, after 72 hours of treatment.  
3.3 Effectiveness of third line ALK inhibitor in vivo 
After having evaluated lorlatinib’s potential in vitro, the next logical step was to see if 
this ALK inhibitor has the same promising effect in vivo at reducing tumour growth. 
Going into the mouse to confirm in vitro results is an imporant process in the preclinical 
pipeline before an inhibitor is allowed to be tested in clinical trials in humans. For drug 
testing, there are certain aspects which cannot be modeled in vitro, which is why in vivo 
tests are a necessity to evaluate factors such as BBB penetrance, pharmacokinetics, drug 
metabolism and microenvironment. All these aspects need to be considered to assess 
the activity and toxicity of a compound before testing it in humans. 
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3.3.1 Lorlatinib successfully decreases tumour growth signal 
To test in vivo efficacy, BI#190 cells were intracranially injected at 5x105 cells into the 
striatum of 6-8 week old CD1 female mice. The tumours were allowed to develop for 
two weeks before animals were stratified into three treatment groups based on their 
luciferase signal (rank 1, 4, 7 etc. being assigned to lorlatinib, rank 2, 5, 8 etc. to 
temozolomide, and rank 3, 6, 9 etc. to vehicle control). The animals‘ signal was 
monitored every week in the IVIS® Lumina and normalized to a photon signal intensity of 
4.00x105, which is shown in Figure 24A. It can be clearly seen that the tumour decreases 
in size for the lorlatinib-treated animals, whereas it keeps increasing for the TMZ- and 
vehicle control-treated animals over time until their endpoint. No animal in the latter 
two groups survived longer than 51 days and 37 days after tumour injection and start of 
treatment, respectively. In contrast, all lorlatinib-treated animals, except for two non-
tumour related deaths (hardly any tumour tissue visible histologically), survived the four 
weeks of treatment with the luciferase signal constantly decreasing. However, after the 
end of the four-week treatment period these animals started to develop symptoms due 
to recurring tumour growth (Figure 24A). Nevertheless, macroscopically the tumours 
from the lorlatinib-treated animals were not as vascularised as tumours from the other 
two groups when examined after sacrificing. 
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Figure 24. Reduction in tumour mass under Lorlatinib treatment. A. IVIS images of the tumour growth of 
representative animals under lorlatinib, TMZ and vehicle control treatment normalized to a photon signal 
intensity of 4.00 x 105. a.i. = after injection, o.t = of treatment. B. The percentage growth or reduction of 
luciferase signal detected in the IVIS Imaging system. The asterisks (*) indicate the two animals which died 
from a non-tumour related cause. 
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3.3.2 ALK inhibition in vivo significantly prolongs survival  
The positive effect on tumour volume of lorlatinib treatment was also mirrored in the 
survival of the treated mice (Figure 25). The mean survival of the lorlatinib-, TMZ- and 
vehicle control-treated animals were 49.4 days (range from 19-62 days; mean 57.7 days 
without the two non-tumour-related deaths), 29.1 days (range from 22-37 days) and 
27.9 days (range from 22-37 days), respectively. Lorlatinib treatment therefore 
significantly increases survival compared to TMZ or vehicle control treatment 
(p<0.0001).  
Not only overall survival, but also potential toxicities should be considered in the 
evaluation of successful treatments in vivo. Weight loss is one of the negative side 
effects of treatment (others include gastrointestinal problems or lethargy) and should 
therefore be avoided if possible. The good response to lorlatinib treatment was not 
accompanied by any such negative side effects. The weight change of all mice in the 
three different treatment groups is illustrated in in Figure 25B. The mean weight of the 
three treatment groups is not significantly different. In addition, the lorlatinib-treated 
group also did not show any other adverse side effects when being treated, which is a 
positive sign for translation of this compound into the clinic. 
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Figure 25. Kaplan-Meier survival curve of CD1 tumour-bearing mice on treatment of either the ALK 
inhibitor Lorlatinib, it’s vehicle control and the standard-of-care in the clinic, Temozolomide and the 
mean body weight whilst under treatment. A. Kaplan-Meier survival curve with indications of start and 
end of treatment at 14 days post intracranial injection for four weeks. Lorlatinib treatment significantly 
increased the survival of PPP1CB:ALK tumour bearing mice. The significance test of choice was the Log-
rank (Mantel-Cox) test with p-values of 0.0001 for lorlatinib vs. TMZ survival and lorlatinib vs. vehicle 
control survival. B. Mean body weight with s.d. bars shown for the three treatment groups, which all lie 
within the normal body weight for wild-type CD1 mice. 
3.3.3 Lorlatinib effectively diminishes pALK signal and reduces proliferation in vivo  
To test the dephosphorylation properties of lorlatinib on the ALK-positive tumour cells 
as well as seeing if it is efficient at reducing cell proliferation, it was planned to 
investigate tumours from lorlatinib- and vehicle control-treated animals using Western 
blot and IHC stain against Ki67, respectively. Keeping in mind that lorlatinib is supposed 
to block the ATP site of the ALK receptor, a reduction in phosphorylation was expected 
in these samples compared to the vehicle control brains similar to the in vitro results 
shown in Figure 21. However, the tumours had reduced drastically in size after three 
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days of treatment (Figure 26), which made it not possible to extract any tumour tissue 
for protein extraction and subsequent Western blot against p-ALK. When repeating this 
experiment, the drug concentrations should be measured in the animals’ brains and 
compare to the drug plasma levels 
Nevertheless, I would like to hypothesise what was expected from this in vivo Western 
blot. With similar total ALK signals, p-ALK signal would only have been detectable from 
the vehicle control-treated brains with lorlatinib-treated brains showing a significant 
decrease in such signal, similar to the in vitro results. Cleaved Caspase 3 would only have 
been detected in the vehicle control brains showing activation of Caspase 3 and 
therewith marking the apoptotic process. A possible explanation why lorlatinib-treated 
brains show no Caspase activation although in vitro results have shown that tumour cells 
enter apoptosis upon ALK inhibitor treatment might be the size of the tumour. The 
tumours had reduced drastically in size after three days of treatment (Figure 26) so that 
the dead cell clearance from within the tumour was more effective due to better 
penetration and shorter distance from within the tumour to the outside. It is more 
difficult to drain apoptotic or dead cells from the tumour mass when the tumour is more 
compact and bigger in size. The reason for dead cells being detected in in vitro samples 
is due to high centrifugation of the harvested treated cells in this artificial setting 
compared to in vivo where the microenvironment also plays a major role.  
Ki67 is a proliferation marker commonly used to detect dividing cells, therefore a 
decrease in Ki67 staining in the lorlatinib-treated brain is expected due to the compound 
blocking tumour growth. 
Figure 26 shows the H&E stainings of three brains each from the lorlatinib and vehicle 
control group, where the animals were only treated for three days and then sacrificed 
one hour after the last dose. The H&E stainings already show the drastic effect lorlatinib 
has on the tumour even after such a short period of time. In two of these tumours, one 
cannot even see tumour tissue anymore and the tumour that is still visible in the third 
animal is very small. The tumours from the control animals are bigger and show a 
stronger H&E staining. The same applies to the Ki67 staining. The Ki67 staining for the 
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vehicle control-treated animals is much stronger than for BI#336 (lorlatinib-treated). For 
two of the ALK inhibitor treated animals, no Ki67 staining was possible, because there is 
no tumour visible anymore in the H&E staining. From this, one can conclude that 
lorlatinib acts extremely rapidly to decrease the proliferation of the tumour cells and 
induce cell death, which makes the lorlatinib-treated tumours smaller than the vehicle 
control-treated ones already after three days of treatment twice daily.  
 
Figure 26. H&E staining and IHC staining against Ki67 of three exemplary lorlatinib- and vehicle control-
treated animals. A. H&E and close-up IHC images against Ki67 of lorlatinib-treated animals. B. H&E and 
close-up IHC images against Ki67 of vehicle control-treated animals. The tumours seen in B are bigger and 
stain much more strongly for the proliferation marker Ki67 compared with lorlatinib-treated animals in A. 
Scale bar: 200µm. 
3.4 Further applications of the mouse model development pipeline 
Another recurring event that came to our attention through tumour profiling programs 
such as the INFORM and ICGC PedBrain projects was the fusion of NTRK-family 
oncogenes (NTRK1/2/3) through chromosomal translocation. These gene fusions were 
found in different biological entities, including pilocytic astrocytoma, infant hemispheric 
gliomas (with a typical age at diagnosis under 24 months) and a group of adult IDH 
wildtype tumours termed ‘anaplastic neuroepithelial tumour with condensed nuclei’ 
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(ANTCN). To date, the original histological and radiological diagnoses of the latter two 
groups of patients is highly varied, since they have not been formally recognised as 
distinct subgroups. This therefore has an impact on treatment planning, with some 
patients receiving a low-grade glioma or even embryonal tumour therapy, and those 
diagnosed as HGG receiving TMZ chemotherapy and (for older patients) radiotherapy. 
There is no clear NTRK-targeted standard of care treatment available yet, and in many 
cases this alteration would not be tested for because of a lack of appreciation that this 
defines a biologically distinct entity, which at least in the case of the adult tumours 
seems to hold true (Ismer et al., in preparation). NTRK fusion was therefore considered 
as a good candidate to further support our statement about in utero electroporation 
being a good method for somatic gene transfer for tumour model development. A 
QKI:NTRK2 fusion gene (first identified in a PA) was injected and electroporated in utero 
into pregnant CD1 mice at E14.5. Figure 27 below shows that also with this candidate 
gene, tumours develop almost exclusively when in combination with a guide RNA 
against cdkn2a or p53. No tumours developed from just the fusion alone indicating that 
a second hit of a knock-out of a tumour suppressor gene is needed for oncogenic 
transformation. Indeed, around half of the human patients with a putative ANTCN 
tumour also showed deletion of cdkn2a/b 
Finally, two hotspot FGFR1 mutations at positions 546 and 656 also gave tumours, 
through p0 injection or in utero electroporation, respectively (Figure 27). These 
alterations are found in paediatric LGGs including PA and, more frequently, 
dysembryoplastic neuroepithelial tumour (DNET), and also represent a promising drug 
target. On the other hand, another promising gene fusion found mostly in paediatric 
LGGs was MYB:QKI, which when electroporated alone or in combination with sgcdkn2a 
did not develop a single tumour after one year on observation.  
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Figure 27. Kaplan-Meier survival curve of other candidate genes p0 injected or in utero electroporated. 
No tumours developed in CD1 mice electroporated with the MYB:QKI fusion (alone or in combination with 
sgcdkn2a) or the QKI:NTRK2 fusion alone. However, when combining the latter fusion with sgp53 or 
sgcdkn2a, the mice develop tumours at 43 days and 75 days on average. The FGFR1 mutation at amino 
acid 546 can most likely be modelled using the RCAS/T-va system at p0, whereas the FGFR1 mutation at 
amino acid 656 more efficiently gave tumours when delivered via in utero electroporation. 
The mean latency of QKI:NTRK2 tumours in combination with sgcdkn2a and sgp53 are 
75 (50 days without the latest outlier at 293 days; n=9/10) and 43 (n=12) days, 
respectively. These time points are only a few days higher than the ones for the 
PPP1CB:ALK fusion. In both cases, however, the fusion in combination with sgp53 gives 
the lowest latency, suggesting that this may have the highest tumourigenic potential 
when used in combination as a second hit. No tumours developed from just the 
QKI:NTRK2 fusion from in utero electroporation. 
The histological stainings of the QKI:NTRK2 fused tumours (Figure 28A) also here clearly 
show that the tumour seen in the H&E staining matches the positive signal of the HA-tag 
in the IHC staining, meaning that the tumour arose from the somatic gene transfer of 
the in utero electroporation. Figure 28B shows that the cells taken into culture from 
these mice brains, express the QKI:NTRK2 fusion by staining against the HA-tag on 
Western blot, further supporting the IHC staining results. 
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Figure 28. Proof of QKI:NTRK2 identity by histological stainings and Western blot. A. H&E and the 
respective IHC staining against HA-tag. The positive IHC stainings clearly correlate with the tumour seen in 
the H&E staining. The magnified images show a close up of the positive HA-tag staining with the scale bar 
of 100µm. B. The tumour cells taken into culture from the other hemisphere of these brains were 
evaluated and stained for HA-tag. All derived tumour cell cultures express the HA-tag and therefore the 
QKI:NTRK2 fusion protein. 
4. Discussion 
85 
 
4. Discussion 
A key aspect in translational oncology is the identification of novel tumour-driving gene 
alterations in patients followed by the generation of representative mouse models in 
order to test specific, more tailored therapies on them. This is exactly the pipeline that 
was described in this work using in utero electroporation as the delivery method of 
different somatic gene alterations to generate a variety of mouse models of relevance to 
paediatric gliomas. The necessity of mouse models has long been recognised, because in 
vitro systems lack the tumour complexity normally found in vivo and do not recapitulate 
the tumour microenvironment211. 
The electroporation method used here overcomes hurdles of some other murine model 
systems in cancer biology. For example, generating GEMMs is a lengthy process, which 
cannot keep up with the speed of new alterations being identified in tumour-sequencing 
projects. PDX models on the other hand always depend on fresh human tumour tissue 
being available (which is sadly still not collected as standard in most centres, and is 
always subject to competing demands from diagnosticians and researchers); they lack 
some levels of tumour complexity that needs to be accounted for in drug tests, e.g. 
tumour microenvironment, and many tumour types will not grow as a PDX187,212-214. In 
utero electroporation allows for somatic overexpression as well as gene knock-outs to 
be modelled at the same time within a very short time frame. It was shown that the 
timing of the manipulation of the developing mouse brain is critical and the outcome 
varies drastically between two different paediatric time points. The mouse models 
described here nicely recapitulate the human counterpart histologically and molecularly. 
The cloning of such constructs can be performed in a reasonably timeframe, and tumour 
development driven by the PPP1CB:ALK or QKI:NTRK2 fusions had a reasonably short 
latency, which means that preclinical results can be generated quickly and translated 
into the clinic. The results obtained above will be systematically evaluated and discussed 
below. 
 
 
4. Discussion 
86 
 
4.1 Efficiency of in utero electroporation 
One point for discussion is clearly the efficiency of the in utero electroporation- only 15% 
of all electroporated pups were found to carry the transgene from which tumours arise. 
When initially trying the surgery at E13.5 like other groups have published215,216, the 
observed efficiency was even lower. Multiple adjustments were then made to the 
surgery technique, post-surgical care, needle preparation and other parameters in order 
to try to improve this. As such, the 15% efficiency rate represents an improvement on 
previous attempts with this approach, and can be accepted as a method to be further 
used for the development of paediatric brain tumour-relevant mouse models. 
Allografting of derived tumour cells, as for the in vivo preclinical testing presented here, 
was more efficient for tumour development due to syngeneity of isolated and cultures 
tumour cells and can therefore help to reduce the total number of animals required. As 
seen in the comparison of the in utero electroporation and RCAS-p0 injection method, 
the time of gene manipulation in the embryonic/neonatal mouse brain is crucial, and the 
former method seems to better recapitulate the time point of development in humans 
for certain genetic alterations. Given the challenges of manipulation at this age, the 
success rate is always likely to be somewhat reduced. Given the value of these models 
for their preclinical utility in a devastating childhood disease, it is felt that the 
harm/benefit ratio can be accepted here. 
4.2 Murine vs. Human PPP1CB:ALK tumours  
The tumours developed from in utero electroporated animals recapitulate the human 
situation, where both develop in a paediatric setting where it is very unlikely that 
environmental factors could have played a major role. Interestingly, ALK-positive NSCLC 
is associated with patients of younger age with a non-smoking history and no EGFR 
mutations126,127, suggesting that this is another setting in which ALK fusion can serve as a 
strong oncogenic inducer with relatively few co-mutations. Knowing that the tumour-
inducing genetic aberrations happen early in development (ALK fusion-positive patients 
are typically less than 2 years old) without any external influences, two different 
methods for the mouse model generation were initially tested. This showed how 
important the time of gene manipulation is when attempting to model paediatric 
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tumours. PPP1CB:ALK-positive tumours developed within a few weeks after in utero 
electroporation at E14.5, whereas mice from the p0 injection - injected only seven days 
later - did not develop tumours. The reason why the p0 injected animals did not develop 
any ALK-positive tumours is most likely due to the absence of the correct cell population 
at this stage of development. Whilst it could be the case that Nestin+ cells (the driver of 
the tva receptor) are not the right population to be targeted by ALK fusions, this system 
generally covers multiple stem and precursor lineages, and has been previously used 
successfully for brain tumour development. Thus, it is thought more likely that by p0 
there is no longer a sufficient population of the right target cells, which are susceptible 
to oncogenic transformation. The cells of origin of paediatric tumours are difficult to 
define due to the highly dynamic environment during early development203,217-219. 
Therefore, it is difficult to predict in advance precisely the right target population – 
further rationale for taking a multi-pronged approach similar to that used here. It is not 
believed that a simple lack of oncogenic potential of the PPP1CB:ALK fusion could be the 
reason for the lack of RCAS tumours, given the success of the EP model and the well-
established driving role of ALK in several other tumour types220-226. 
Although the murine tumours histologically recapitulate the human tumours well, one 
needs to keep in mind that all of the post-characterisation was done on ALK fusion 
tumour cells with a second hit of either cdkn2a or p53, of which neither are normally 
found in the clinical situation. For a preclinical model, a mean latency of 137 days (as 
seen with the ALK fusion alone) is too long when one has the opportunity to use a faster 
mouse model, which also recapitulates the human tumour in terms of histological 
morphology. However, it was of interest to assess how oncogenic the BI#271 cells, i.e. 
ALK fusion cells without a second hit, are when allografted into CD1 mice and compare 
that to the allografted BI#190 cells used for the inhibitor testing. For that, BI#271 cells 
were reinjected into five CD1 mice (Figure 29), which were monitored for tumour-
related symptoms. Four of the five allografted mice developed a tumour, giving these 
cells a penetrance of 80%. The fifth mouse was sacrificed 79 days after tumour cell 
injection, because of the lack of luciferase signal throughout the experiment. 
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Figure 29. Kaplan-Meier survival curve of BI#271 allografted CD1 mice. The mean latency of the four 
mice that developed a tumour was 28.5 days. The fifth mouse was sacrificed after 79 days due to lack of 
luminescence signal being detected, meaning that the tumour cells did not engraft.  
The mean survival of the four tumour-bearing mice injected with ALK fusion-only cells 
was 28.5 days and shows that even without a knock-out of cdkn2a or p53, these cells are 
oncogenic enough to form tumours again. Therefore, the next step to make this model 
recapitulate the human situation more closely, would be to repeat the inhibitor testing 
on BI#271-injected mice to see if the positive effect on survival of lorlatinib-treated 
animals can be replicated in these mice. This would make the preclinical pipeline in 
general more representative. These results also give further support to the strategy of 
using allografts of initially generated tumours for further expansion, both to increase 
efficiency of tumour development over in utero EP alone and to reduce latency.  
Another interesting point that should be tested is a potential resistance mechanism of 
tumour cells against lorlatinib. It was shown that NSCLC cells developed resistance 
against the first line ALK inhibitor crizotinib, leading to the development of alectinib and 
ceritinib targeting the mutations that arose from crizotinib treatment. Testing for a 
resistance mechanism caused by lorlatinib could be done in various ways. For example, 
the in vivo testing with lorlatinib could be repeated to the point where the tumours start 
to grow back after initial stop of treatment. After that, the mice could be treated with 
lorlatinib again to see if the initial response on treatment can be recapitulated a second 
time. If this is the case, it would reassure that a ‘drug holiday’ alone would be unlikely to 
induce lorlatinib resistance in ALK positive cells. Subsequently, the initial treatment 
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could be extended until the tumours recur while still under therapy, at which point they 
could be molecularly profiled to look for possible secondary hits accounting for the 
resistance. No signs of resistance were observed during the (admittedly relatively short) 
period of drug administration used here. 
4.3 Differences in drug responses to ALK inhibitors in vitro 
Another aspect to be considered is the different drug response in vitro of BI#271 cells 
compared to the other primary tumour cell cultures. This is another reason for doing the 
in vivo test of reinjected BI#271 cells into CD1 mice to see if the lorlatinib treatment 
shows a similar significant benefit in survival. This would be much faster with BI#271 
reinjected tumour cells because of the decreased latency of 28.5 days (Figure 29). As 
seen in Figure 20, the continuous development of specific small molecule inhibitors is 
crucial. The third line ALK inhibitor, lorlatinib, shows the best results in terms of lowest 
concentration at which 50% of tumour cells die (IC50), whereas the first line ALK 
inhibitor, crizotinib, the worst. The tumour cells also respond better to alectinib, a 
second line ALK inhibitor, developed after ALK-positive tumours showed resistance to 
crizotionib, than to crizotinib. This shows that continuous work needs to be conducted 
on possible resistance mechanisms and on further exploring more potent compounds, 
even after one drug in a given class has already been approved for clinical use. Indeed, 
the generations of ALK inhibitors are a good example of this, whereby NSCLC patients 
being treated with crizotinib developed resistance which could be overcome by 
subsequent compounds123,227,228. 
4.4 Drug’s mechanism of action 
Before discussing the results of the in vivo study of lorlatinib compared to its vehicle 
control and the standard of care temozolomide, the underlying mechanism of ALK 
inhibitors needs to be evaluated to understand what the drug is doing to the tumour 
cells.  
The cell cycle analysis in Figure 22 shows that ALK fusion cells upon treatment with 
crizotinib or lorlatinib show fragmented DNA, meaning they have either gone into 
apoptosis or necrosis upon treatment. BI#283 cells show a smaller proportion of cells in 
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G0/1 phase after treatment compared to BI#169 cells. This might be due to the deletion 
of p53 in the former cells. P53 for example governs the G1/S phase checkpoint through 
induction of the Cdk inhibitor p21229 and when p53 is missing, gives the cells less time to 
repair DNA, i.e. less time in the G1 phase of the cell cycle230,231. Lukin et al.232 have 
shown that p53 wild type cells go into reversible cell cycle arrest upon 
chemosensitisation to promote cell survival, possibly explaining the higher number of 
BI#169 cells in the G0/1 phase upon treatment. A significant difference in the number of 
cells spent in each cell cycle stage was only detected in crizotinib-treated cells and not 
lorlatinib-treated cells. This is most likely due to the difference in IC50 concentrations 
with IC50 values of crizotinib being 31-fold and 96-fold higher than IC50 values of 
lorlatinib in BI#169 and BI#283 cells, respectively. Thus, a much lower overall 
concentration of lorlatinib is able to achieve approximately the same effect as crizotinib. 
Judging from the IC50 curves, one can predict that lorlatinib will have a stronger effect 
on the cell cycle and apoptosis than crizotinib if both are applied at the same 
concentration.  
The Annexin V staining that followed was conducted to evaluate in which stage of cell 
death these tumour cells are after treatment. The results revealed that a higher 
percentage of cells after three days of lorlatinib treatment are in necrosis, which is 
described as an “irreversible disturbance of cellular homeostatic mechanisms”207. As 
necrosis is only a state describing the presence of dead tissue233-235, one can only assume 
which cell death pathway these cells underwent to become necrotic. For that, the flow 
cytometric analysis would need to be repeated in a time course experiment to safely say 
that cells went into apoptosis first and then ended up in apoptotic necrosis236. Another 
necessary experiment to confirm this hypothesis is to use a different IF staining protocol 
and stain the treated cells without washing away potentially apoptotic or necrotic cells 
and look at their morphology and/or stain for necrotic and apoptotic factors. 
Understanding the potential underlying mechanism of action of both tested ALK 
inhibitors, the results obtained from the in vivo drug treatment should be discussed. 
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4.5 Significant survival advantage of lorlatinib-treated animals and lack of 
efficacy of TMZ 
Another somewhat surprising observation made from this experiment is the similarity in 
survival and tumour growth rate of the TMZ-treated animals compared to the vehicle 
control animals (Figure 24 and Figure 25). While lorlatinib shows significant tumour 
regression in vivo and increases survival, TMZ shows almost the same results as the 
vehicle control, although it is used as standard of care in the clinic for different 
gliomas237-241. TMZ is used in the clinic as a standard of care for patients with high-grade 
glioma at the moment, because no ALK inhibitor is approved in paediatrics yet and ALK 
has not yet been formally described as a distinct entity in paediatric brain tumours to 
suggest ALK inhibitors as a better choice for the 5% of patients carrying an ALK fusion. 
Based on the preclinical results shown here, choosing TMZ for the treatment of ALK 
fusion brain tumours does not seem ideal, because TMZ is neither prolonging survival 
nor inhibiting tumour growth in any way in vivo. In addition, many groups have reported 
resistance mechanisms against TMZ and recurrence of tumours during or after TMZ 
treatment241,242. It has also been shown by others that TMZ fails to improve the 
outcome243 in children with high-grade astrocytomas for example34, but yet, it is still 
used in many patients, because no other more specific or effective treatment is 
available. 
It is therefore important to accelerate the clinical trial pipeline of lorlatinib (and other 
rationally-targeted compounds) in paediatric brain tumour patients to enable them to 
receive the best possible treatment strategy based on promising results from this study 
and others. 
4.6 Not all candidate genes are suitable for in vivo modelling 
Whilst multiple driver genes successfully generated tumour models during the course of 
this study, it should be noted that the methodologies described are not 100% efficient 
when applied with any gene alteration found in the sequencing of the patient’s tumour. 
There are potential oncogenic driver mutations found in the clinic that do not develop 
into tumours in the mouse using the somatic gene transfer method of in utero 
electroporation. One example for that is the MYB:QKI fusion, which does not lead to 
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tumour development and growth in vivo within one year of surgery either in 
combination with sgcdkn2a (n=9) or alone (n=7). Potential reasons for this could be that 
the wrong cells are hit, i.e. too early or late in development where the introduction of 
this oncogenic fusion at E14.5 does not have a strong enough effect on the cells 
anymore to transform into tumour cells, similar to the PPP1CB:ALK fusion at the p0 time 
point. Another possible explanation could be that the MYB:QKI fusion itself is not 
oncogenic enough to form tumours at the injected concentration, or that other 
intracellular stimuli are needed in addition to make this fusion oncogenic. 
4.7 Future directions for NTRK2-fused cells 
None of the points mentioned in 4.6 apply to the QKI:NTRK2 fusion mouse model, which 
successfully developed tumours with a mean survival of 75 and 43 days in combination 
with cdkn2a and p53 knock-out, respectively. The next step for this project would be to 
follow the preclinical pipeline established for the ALK fusion tumours, after further 
characterisations of the tumour to prove that the tumours truly recapitulate their 
human counterparts as closely as possible. The most promising NTRK inhibitor in 
development at present, and used in paediatric clinical trials already, is larotrectinib 
(LOXO-101). Many clinical case reports have shown that this drug, taken once daily 
orally, can give tremendously positive results with treated tumours often not visible on 
MRI anymore after a given period. To further enhance the possible benefits of this 
compound, more supporting preclinical trials are needed to better understand the 
functional consequences of inhibition; biomarkers of sensitivity or primary resistance, 
and possible mechanisms of acquired resistance. Additional models will help to achieve 
this goal, which will hopefully help paediatric HGG patients whose tumour harbours an 
NTRK gene aberration. 
4.8 Conclusion 
Finally, the work of this thesis touches on the importance of developing better clinical 
trials for paediatric cancer patients, and with that, the crucial role for analysis of 
individual tumour tissue on a molecular level. The MNP2.0 study has shown that 
histological diagnosis can be discrepant to the molecular one in up to 15-20% of cases 
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due to overlapping and hard to distinguish histological features of the tumours, 
especially in the interface/overlap between paediatric low-grade gliomas and high-grade 
gliomas. Such discrepancies can have serious adverse effects for patient management. In 
general, the approach of treating with non-specific “one-size-fits-all” 
chemotherapeutics, like TMZ leading to serious side effects and no significant reduction 
in tumour growth, also needs major rethinking. This development of changing from 
purely histological to a combination diagnosis of histological and molecular analysis 
requires more efforts in terms of discovery, education, and access to testing, but several 
examples have shown that molecular diagnoses have the potential to improve patient 
management and provide better prognostic value. 
Studies like INFORM and MNP2.0 enable us to identify driver mutations on a case by 
case basis and pick up on novel targets, such as ALK, that may not have previously been 
recognised. The work in this thesis mostly addresses the next step, moving from 
identifying tumour-causing mutations to developing and pre-clinically treating 
respective mouse models and translating the findings back to the clinic; potentially 
advising clinicians on the best treatment strategy for each novel gene aberration. 
Targeted inhibition in paediatric patients is only just starting to become more 
widespread, so therefore clinical results as to how progression-free survival changes 
with these targeted therapies can only be expected in the next few years. Nevertheless, 
this is why preclinical data is so important to accelerate this process of starting clinical 
trials and ultimately approving new treatments for children.  
With continued efforts to keep molecularly analysing patients’ tumours and developing 
the analytical methods further, we can ensure that the patients will receive the best 
possible therapy based on their personally identified mutational burden. The above 
described pipeline allows for faithful recapitulation of key driver events (i.e. recurrent 
gene alterations in a number of patients) in a relatively rapid manner. This is particularly 
promising for oligo mutated tumours, i.e. paediatric tumours, where the one tumour 
driving alteration can be targeted, hopefully ensuring that the tumour does not use one 
of the other pathways affected to evade treatment action. That is different and more 
difficult in adult tumours due to their tumours heterogeneity and genetic complexity.  
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This work will hopefully contribute to a faster bench to bedside workflow of tailored 
therapy and accelerated approval of new compounds for paediatric low- and high-grade 
gliomas, thereby assisting in the goals of minimising toxicity for patients and improving 
progression-free and overall survival. 
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zusprichst, wenn ich Zweifel habe, dass du mir gezeigt hast was Lebensfreude und 
Lebenswillen ist und danke, dass du mir gezeigt hast, dass es sich lohnt für Dinge zu 
kämpfen egal wie (gut) die Chancen stehen. Ich habe dir so viel zu verdanken und habe 
aber leider keine Chance mehr bekommen es dir so zu zeigen wie du es verdient hättest. 
Danke, dass du der beste Onkel warst, den ich mir je hätte wünschen können.  
Ich liebe dich bis zum großen Wagen und zurück! 
